Book
Chapters

1. Lockey RF, Bukantz SC:
   Allergic Emergencies.

2. Lockey RF, Bukantz SC:
   Urgencias Alergicas.
   Clinicas Medicas de Norteamerica, Alergia en adultos,

3. Lockey RF, Bukantz SC:
   Diagnostic Tests and Hyposensitization Therapy in Asthma.
   In: Bronchial asthma, Mechanisms and Therapeutics.
   Weiss EB, Segal MS (eds).

4. Lockey RF:
   Immunopathologic (allergic) Mechanisms.
   In: Allergy and Clinical Immunology.
   Lockey RF (ed).
   Medical Examination Publishing Co, Inc. Garden City,

5. Lockey RF, Bukantz SC:
   Allergic Emergencies.
   In: Allergy and Clinical Immunology.
   Lockey RF (ed).
   Medical Examination Publishing Co, Inc, Garden City,

6. Lockey RF:
   Glucocorticosteroids in Treatment of Asthma and Allergic
   Disease.
   In: Allergy and Clinical Immunology.
   Lockey RF (ed).
   Medical Examination Publishing Co, Inc, Garden City,

7. Lockey RF:
   Member of Panel on Allergic Emergencies, U.S.
   Department of Health, Education and Welfare. NIAID
   Task Force Report:
   Asthma and the Other Allergic Diseases.
8. Lockey RF, Bukantz SC: 
   Allergy and Asthma. 
   In: Sodeman’s Pathologic Physiology, Mechanisms of Disease. 
   Sodeman WA, Sodeman TM (eds). 

9. Parrino J, Lockey RF: 
   Allergic Reaction to Insect Stings. 
   In: Current Therapy. 
   Conn HR (ed). 

10. Lockey RF: 
    Allergic and Other Adverse Reactions Caused by the Imported fire 
    Ant. 
    In: Advances in Allergology and Applied Immunology. 
    Oehling A, Glazer I, Mathov E, Arbesman C (eds). 

11. Lockey RF, Stablein JJ: 
    Ants and Human Anaphylaxis. 
    In: Monograph on Insect Allergy. 
    Levine M, Lockey RF (eds). 

12. Bukantz SC, Lockey RF, Fenske NA, Donelau PA, Flowers FP: 
    Allergy, Immunology, Dermatology. 
    In: Sodeman's Self-Assessment of Current Knowledge in Internal Medicine, Sixth 
    Medical Examination Publishing Company, New Hyde Park, 
    New York, pp 82-9, 1982.

13. Fox RW, Lockey RF: 
    Immediate Hypersensitivity and Immune Complex Disease. 
    In: Circulating Immune Complexes in Clinical Medicine. 
    Espinoza LR, Osterland CK (eds). 

14. Lockey RF, et al: 
    Primer on Allergic and Immunologic Diseases. 
    Contributor. 

15. Lockey RF: 
    Allergic Reactions to Insect Stings. 
    In: Conn's Current Therapy. 
    Rakel RE (ed). 

16. Samaan SS, Fox RW, Bukantz SC, Lockey RF: 
    Comparison of Diurnal and Nocturnal Theophylline Levels at Steady-State 
    In: Annual Review of Chronopharmacology. 
    Rembing A, Smolensky M, Labresque G (eds). 
17. Lockey RF:
   Allergic Reactions to Insect Stings.
   In: Conn's Current Therapy.
   Rakel RE (ed).

18. Stablein JJ, Lockey RF:
   Ants and Human Anaphylaxis.
   In: Monograph on Insect Allergy.
   Levine ME, Lockey RF (eds).
   American Academy of Allergy and Immunology.

19. Fox RW, Lockey RF:
   The Role of Immunotherapy in Asthma.
   Gershwin ME (ed).

20. Samaan SS, Fox RW, Bukantz SC, Lockey RF:
   The Effects of Age and Circadian Rhythm on Theophylline Pharma-1 Kokinetis in
   Settipane GA (ed). New England and Regional Allergy Proceedings, Providence, RI,

21. Lieberman P, Stablein JJ, Lockey RF:
   Drug Allergy.
   In: Allergy, An International Textbook.

22. Calderon E, Ramirez MA, Arrieta MI, Fernandez-Caldas E, Russell D, Lockey RF:
   Nutritional Disorders in HIV Disease.
   In: Food and Nutrition Science.
   Chandra RK (ed).

23. Fernandez-Caldas E, Reed C, Lockey R:
   Distribution of Indoor Allergens.
   In: Allergen Immunotherapy.
   Lockey R, Bukantz S (eds).

24. Lockey RF, Bukantz SC:
   Allergen Immunotherapy Side Effects.
   In: Allergen Immunotherapy.
   Lockey RF, Bukantz SC (eds).

25. Lockey RF:
   Allergic Reactions to Insect Stings.
   In: Conn's Current Therapy.
   Rakel RE (ed).
26. Bucholtz G, Fernandez-Caldas E, Lockey RF: 
   Allergic Rhinitis Caused by House Dust and other Non Pollen Allergens. 
   Lichtenstein L, Fauci T (eds). 
   In: Current Therapy in Allergy, Immunology, and Rheumatology. B.C. Decker, Inc., 

27. Bukantz SC, Lockey RF: 
   IgE Immediate Hypersensitivity. 
   In: Bronchial Asthma: Mechanisms and Therapeutics. 
   Weiss EB, Stein M (eds). 

28. Fernandez-Caldas E, Garcia-Ramos E, Calderon E, Lockey RF: 
   Antecedentes Historicos, Alergenos y Mecanismos Immunologicos de las 
   Enfermedades Alergicas. 
   In: Epidemiologia Y Factores Desencadenantes De Las Alergias Respiratorias En 
   Tenerife. 
   Consejeria de Sanidad, Trabajo y Servicios Sociales, Gobierno Autonomo de 

29. Garcia-Ramos E, Fernandez-Caldas E, Calderon E, Lockey RF: 
   Asma y Rinitis Alergica: Epidemiologia, Diagnostico, tratamiento y Control 
   Ambiental. 
   In: Epidemiologia Y Factores Desencadenantes De Las Alergias Respiratorias En 
   Tenerife. 
   Consejeria de Sanidad, Trabajo y Servicios Sociales, Gobierno Autonomo de 

30. Fernandez-Caldas E, Garcia-Ramos E, Calderon E, Lockey RF: 
   Alergias Respiratorias en Tenerife. 
   In: Epidemiologia Y Factores Desencadenantes De Las Alergias Respiratorias En 
   Tenerife. 
   Consejeria de Sanidad, Trabajo y Servicios Sociales, Gobierno Autonomo de 

31. Bukantz SC, Lockey RF: 
   Adverse Effects and Fatalities Associated with Immunotherapy and Skin Testing. 
   Lockey RF (assoc ed). 
   American Academy of Allergy and Immunology, Milwaukee, Wisconsin, 

32. Lockey RF, Portnoy JM, Creticos PS: 
   Forms Used for Skin Testing and Immunotherapy. 
   Creticos PS (ed), Lockey RF (assoc ed). 
   American Academy of Allergy and Immunology, Milwaukee, Wisconsin, 

33. Fox RW, Lockey RF: 
   The Role of Immunotherapy in Asthma. 
   In: Bronchial Asthma: Principles of Diagnosis and Treatment. 
   Gershwin ME, Halpern GM (eds). 
34. Ledford DK, Lockey RF:
   Immunotherapy for Allergic Disease.
   In: Allergy, Asthma, and Immunology from Infancy to Adulthood, Third Edition.
   Bierman CW, Pearlman DS, Shapiro GG, Busse WW (eds).

35. Lockey, RF:
   Insect and Arthropod Bites and Stings.
   In: Current Practice of Medicine: Volume 2, Lieberman P. (Section Editor).
   Bone RC (Series Editor).

36. Szentivanyi A, Abarca CM, Brooks SM, Lockey RF, Prockop LD:
   Some Evolutionary, Morphoregulatory, and Functional Aspects of the Immune-
   Neuroendocrine Circuitry.
   In: Immunopharmacology Reviews, Volume 2.
   Hadden JW, Szentivanyi A (eds).

37. Puerta L, Fernandez-Caldas E, Lockey RF:
   Indoor Allergens: Detection and Environmental Control Measures.
   In: Indoor Air Pollution and Health.
   Bardana EJ, Jr. and Montanaro A (eds).

38. Fox RW, Lockey RF:
   Allergen Immunotherapy.
   In: Allergic Diseases: Diagnosis and Treatment.
   Lieberman P and Anderson JA (eds).

39. Lockey RF:
   Allergic Reactions to Insect Stings

40. Nelson RP, Lockey RF:
   Rhinitis and Sinusitis
   In: Environmental and Occupational Medicine, 3rd edition.
   William N. Rom, M.D., M.P.H. (ed)

41. Lockey RF, Nicoara-Kasti G:
   Insect and Arthropod Bites and Stings
   In: Current Practice of Medicine, Volume 1, Number 1
   Fitzgerald FT (editor-in-chief)
   Lieberman PL (section editor)
42. Bukantz SC, Lockey RF, Kasti GL: 
Adverse Effects and Fatalities Associated with Allergen Immunotherapy 
In: Allergens and Allergen Immunotherapy, 2nd edition. 

43. Mohapatra SS, Lockey RF: 
Weed Pollen Allergens 
In: Allergens and Allergen Immunotherapy, 2nd edition. 

44. Fernandez-Caldas E, Puerta L, Lockey RF: 
Mite Allergens 
In: Allergens and Allergen Immunotherapy, 2nd edition. 

45. Nelson RP, Lockey RF: 
Selected Immunotherapy Patient Instructions and Consent Forms 

46. Lockey RF, Rosenbach KP, Nelson RP: 
Insect Sting Hypersensitivity 
In: Conn’s Current Therapy, 1999 edition. 
Robert E. Rakel, M.D. (ed) 

47. Fox RW, Lockey RW: 
Allergen Immunotherapy In: An Expert Guide to Allergy 

48. Bousquet J, Lockey RF, Malling HJ: 
Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases (WHO Position Paper, Executive Summary)In: Immunotherapy in Asthma 

49. Lockey RF, Nelson RP: 
Insect and Arthropod Bites and Stings. 
In: Current Practice of Medicine, Volume 2, Number 9 
Gotto AM (editor-in-chief) 
Lieberman PL,(section editor) 

50. Mohapatra SS, Lockey RF: 
Allergens 
In: Current Review of Allergic Diseases 
Kaliner MA, M.D. (ed) 
51. Morena M, Lockey RF:  
Insect Allergy  
In: Allergy in Primary Care  
Altman LC, Becker JW, Williams PV (eds)  

52. Mohapatra SS, Lockey RF:  

53. Ramirez NC, Lockey RF:  
Management of Acute Asthma in the Office Setting.  

54. Codina R, Lockey RF:  

55. Lockey RF, Slater JE, Esch RE:  

56. Lockey R, Reichmuth D:  


58. Mohapatra SS, Lockey RF, Polo F:  

59. Fernández-Caldas E, Puerta L, Caraballo L, Lockey RF:  

60. Müller U, Golden DBK, DeMarco PJ, Lockey RF:  
61. Bukantz SC, Lockey RF:  
Adverse Effects and Fatalities Associated with Subcutaneous Allergen 
Immunotherapy. In: Allergens and Allergen Immunotherapy, 3rd ed. Lockey RF,
Bukantz SC, Bousquet J (eds). Marcel Dekker, Inc., New York, NY,

62. Cox L, Lockey RF:  
Instructions and Consent Forms for Allergen Immunotherapy. In: Allergens and 
Allergen Immunotherapy 3rd ed. Lockey RF, Bukantz SC, Bousquet J (eds). 

63. Lockey RF, (contributor):  
In Prevention of Allergy and Allergic Asthma. World Allergy Organization,
Johansson SGO, Haahtela T (eds.) Karger, Basel, Switzerland, Preventive 
Measures: Section 1: Early Interventions, pp. 135-151, Allergy and Asthma 

64. Codina R, Ramey J, Lockey R:  
Allergen Immunotherapy. In: Atlas of Allergic Diseases, 2nd ed. Lieberman PL,

65. Nelson RP, Lockey RF:  
Insect Allergy. In: Atlas of Allergic Diseases, 2nd ed. Lieberman PL, Blaiss MS 

66. Fox RW, Lockey RF:  
Allergen Immunotherapy. In: Allergic Diseases – Diagnosis and Treatment,

66. Cole SL, Lockey RF:  
Subcutaneous Allergen Immunotherapy and its Mechanisms. In: Recent Trends in 
Aerobiology, Allergy and Immunology. Vijay HM, Kurup VP (eds). Research 

67. Slater JE, Esch RE, Lockey RF:  
Preparation and Standardization of Allergen Extracts. In: Middleton’s Allergy: 
Principles & Practice, 7th edition. Adkinson NF, Jr, Bochner BS, Busse WW, Holgate 
ST, Lemanske RF, Jr, Simons FER (eds). Mosby, 1(7): Chapter 34, 

68. Mohapatra SS, Lockey RF, Polo F:  
Weed Pollen Allergens. In: Allergens and Allergen Immunotherapy, 4th ed. Lockey 
RF, Ledford DK (eds). Informa Healthcare, New York, NY. Chap. 8, pp.127-139, 
2008.

69. Fernández-Caldas, E, Puerta L, Caraballo L, Lockey RF:  
Mite Allergens. In: Allergens and Allergen Immunotherapy, 4th ed. Lockey RF,

70. Müller U, Golden DBK, Lockey RF, Shin B:  
Immunotherapy for Hymenoptera Venom Hypersensitivity. In: Allergens and 
Allergen Immunotherapy, 4th ed. Lockey RF, Ledford DK (eds). Informa Healthcare, 


ABSTRACTS: (* presented)


*3. Zeiss CR, Lockey RF:
   An Extended Refractory Period to Adverse Effects of Aspirin in a Patient With the ASA-Triad.

*4. Lockey RF:
   Systemic Reactions to Stinging Ants.

*5. Bukantz SC, Lockey RF, Baird I:
   Diverse Reactivity of Cat Dander Extracts.

*6. Parrino J, Kandawalla N, Lockey RF:
   Treatment of the Local Skin Response to Imported Fire Ant Sting.

*7. Phillips JW, Goldman AL, Lockey RF:
   Bahia Grass Pollen - an Important Aeroallergen.

*8. Bukantz SC, Lockey RF, Baird I:
   Studies With Cat Saliva Allergen.

*9. Adelman HM, Lowenstein MB, Trunnell T, Lockey RF:
   Urticaria and Eosinophilic Fascitis.

    Hymenoptera Venom Study. Committee on Insects.

*11. Lockey RF, Fox RW, Bukantz SC:
    Neurologic Sequelae (NS) Following the Imported Fire Ant (IFA) Sting.

    Effects of the Toxin of Red Tide, Ptychodiscus revis (PB), on Canine Tracheal Smooth Muscle.

    Contractile Effects of Ptychodiscus brevis Toxin on Canine Airways Smooth Muscle.

    Immunologic aspects of Fixed Drug Eruptions.
   *Annals of Allergy* 47:120, 1981.

*16. Fox R, Bukantz S, Samaan S, Lockey R: 
   Theo-Dur Bioavailability in Geriatric age Group. 

*17. Stablein JJ, Binford LR, Bukantz SC, Lockey RF: 
   Melaleuca (M) Tree and Respiratory Disease. 

*18. Krzanowski JJ, Asai S, Martin DF, Lockey RF, Bukantz SC, Szentivanyi A: 
   Effects of the Imported Fire Ant (Solenopsis invicta) Venom on Canine Tracheal Smooth Muscle Contraction Induced by Axonal Sodium Channel Stimulators (*Ptychodiscus brevis* Toxin, Veratridine and Scorpion Toxin). 

*19. Asai S, Krzanowski JJ, Martin DF, Lockey RF, Bukantz SC, Szentivanyi A: 
   *Ptychodiscus brevis* Toxin (PBTX) Stimulates a New Receptor Site in Activating Parasympathetic Nerve Axonal Voltage-sensitive Sodium Channels. 

*20. Asai S, Krzanowski J, Martin D, Lockey R, Bukantz S, Szentivanyi A: 
   A new parasympathetic axonal sodium channel gate stimulator, *Ptychodiscus brevis* toxin (PBTX). 
   XI International Congress of Allergology and Clinical Immunology, Abstract 42, 1982.

   Pharmacokinetics of theophylline in geriatrics. 

*22. Lockey R, Peppe B, Baird I, Turkeltaub P: 
   Hymenoptera venom study (HVS) safety. 

*23. Peppe BC, Lockey RF, Madden J, Baird I, Turkeltaub P: 
   Hymenoptera venom study (HVS), treatment results. 

*24. Louie SJ, Krzanowski JJ, Bukantz SC, Lockey RF: 
   Ergonovine effects on airway smooth muscle contractile responses. 

*25. Johansson SGO, Lockey RF: 
   RAST studies of allergy to imported fire ant, (IFA), (*Solenopsis invicta*). 
*26. Bucholtz G, Lockey R, Binford L, Serbousek D:  
Allergenicity of the bald cypress tree (*Taxodium distichum*).  

*27. Hensel AE, Lockey RF:  
Death from imported fire ant, *Solenopsis invicta*.  

*28. Wells JH, Lerner MR, Martin DF, Strecker RA, Lockey RF:  
The effect of respiratory exposure to red tide toxin on airway resistance in conscious guinea pigs.  

*29. Samaan S, Fox RW, Bukantz SC, Lockey RF:  
Comparison of theophylline (T) disposition in elderly smokers and non-smokers.  

*30. Fox R, Samaan S, Bukantz S, Lockey R:  
Comparison of diurnal and nocturnal theophylline disposition.  

*31. Lockey R, Fox R, Millns J, Espinoza C, Bukantz S:  
Probable immunologic role of Langerhan's cells in fixed drug eruption (FDE) to pseudoephedrine (PS).  

*32. Fox RW, Samaan S, Bukantz S, Lockey R:  
Comparison of diurnal and nocturnal theophylline disposition.  
First International Montreux Conference on Chronopharmacology,  

*33. Krzanowski J, Sakamoto Y, Duncan R, Martin D, Lockey R, Hunter K:  
The Mechanism of *Ptychodiscus brevis* toxin (PBTX).  
*Pharmacologist* 26:175, 1984.

*34. Sakamoto Y, Krzanowski J, Lockey R, Polson J, Szentivanyi A:  
The mechanism of ergonovine-induced airway smooth muscle contraction.  

*35. Ledford DK, Lockey RF, Serbousek D, Park J, TeStrake D:  
Studies on airborne pollens and fungi during grass mowing.  
Southeastern Branch, American Society for Microbiology,  

*36. Ledford DK, Overman MD, Gonzalvo A, Cali A, Mester SW, Lockey RF:  
Microsporidiosis myositis in the acquired immune deficiency syndrome.  
American College of Allergists, Bal Harbour, Florida,  
February 2-6, 1985.

*37. Lockey R, Benedict L, Turkeltaub P:  
Fatalities (F) from immunotherapy (IT) and skin testing (ST).  
Allergenicity of the Australian pine pollen (Casuarinaequisetifolia).

*39. Nordvall SL, Johansson SGO, Ledford D, Lockey R:
Allergens of imported fire ant (IFA), Solenopsis Invicta.

*40. Krzanowski J, Sakamoto Y, O'Connor C, Ledford D, Krzanowski J, Lockey R:
The acute actions of gold salts on canine tracheobronchial smooth muscle.

*41. Sakamoto Y, Krzanowski J, Lockey R, Polson, Szentivanyi A:
The potential of ergonovine to precipitate bronchial asthmatic attacks via serotonin receptors.

*42. Fox RW, Bukantz SC, Lockey RF:
Treatment of chronic idiopathic urticaria (CIU) with astemizole (A).

*43. Johansson SGO, Nordvall S, Ledford D, Lockey R:
Specific IgE and IgG responses to immunotherapy (IT) with imported fire ant whole body extract (IFA-WBE) in IFA hypersensitivity (H).

*44. Ganguly R, Stablein J, Lockey RF, Baird I, Shamblin P, Serbousek D:
Salivary immunoglobulins in the aged.

*45. Nelson RP, Bucholtz GA, Lockey RF, Baird-Warren I:
Cross-over study of cardiopulmonary effects of subcutaneous (SQ) albuterol (A) and epinephrine (E) in reversible obstructive airway disease.

*46. Ganguly R, Lockey R:
Age interference of lymphokine production by lung derived lymphocytes.

*47. Ledford D, Lockey R, Serbousek D, Park J, Te Strake D:
Studies on airborne fungal spores and pollens during grass mowing.
International Society of Human and Animal Mycoses.
Published abstract, p 27

*48. Shimoda T, Krzanowski J, Lockey RF, Martin D, Duncan R:
The action of a natural environmental toxin, Ptychodiscus brevis, on lower airways.

*49. Ledford DK, Serbousek D, Lockey RF:
The effects of lawn mowing on airborne pollen and fungal spores.


*55. Robicsek S, Polson JB, Krzanowski J, Lockey RF, Szentivanyi A: Separation of lymphocyte cyclic nucleotide phosphodiesterases by ion exchange high pressure liquid chromatography. VIth International Conference on Cyclic Nucleotides, Calcium and Protein Phosphorylation, September 2-7, 1986.


Ledford DK, Bucholtz GA, Lockey RF:
Immunochemical characterization of Bahia grass (Paspalum notatum) pollen extract (BPE) and cross reactivity with aqueous Bahia leaf extract (BLF).

Nelson RP, Bucholtz GA, Minor MW, Ledford DK, Lockey RF:
Bayberry (Myrica cerifera) pollen as an aeroallergen.

Bucholtz GA, Ledford DK, Lockey RF:
Immunochemical characterization of Australian pine (Casuarinaequisetifolia) pollen extract.

Krzanowski J, Shimoda T, Nelson R, Martin DF, Polson J, Duncan R, Lockey R:
*In vitro* red tide toxin effects on human bronchial smooth muscle.

Polson JB, Lockey RF, Bukantz SC, Lowitt S, Krzanowski J, Szentivanyi A:
Effects of ketotifen on the responsiveness of human peripheral blood lymphocyte beta adrenergic receptors.

Krzanowski JJ, Duncan RA, Davis JS, Polson JB, Watanabe T, Lockey RF, Szentivanyi A:
The formation of inositol 1,3,4,5, tetrakisphosphate (IP_4) in isolated contracting canine tracheal smooth muscle.

Fernandez-Caldas E, Fox R, Trudeau W, Swanson M, Reed C, Lockey R:
House dust mite allergy in Tampa, Florida.
42nd Annual Meeting, Southeastern Allergy Assoc., Inc. October 8-10, 1987, Richmond, VA.

Diaz J, Lockey R, Stablein J, Mines H:
Multiple imported fire ant (Solenopsis invicta) stings without systemic effects.
Annual Scientific Assembly of the Southern Medical Assoc. November 1, 1987, San Antonio, TX.

Berman A, Aguilar JL, Espinoza LR, Espinoza CG, Vasey FB, Lockey RF, Germain B:
Identification of human immunodeficiency virus (HIV) antigens in synovial membrane of patients with HIV-associated arthritis.
The 14th Southeastern Regional Meeting of the American Rheumatism Association. December 4, 1987, Nashville, TN.
*71.  Krzanowski J, Watanabe T, Martin D, Polson J, Duncan R, Lockey R:
  Ptychodiscus brevis toxin (PBTX) induced alpha adrenergic contractile responses in
  canine tracheal smooth muscle (CTSM).

*72.  Watanabe T, Krzanowski J, Polson J, Duncan R, Lockey R:
  Age related differences in development of histamine tachyphylaxis in canine airway
  smooth muscle.

*73.  Trudeau W, Fox R, Fernandez-Caldas E, Lockey R:
  Flea, an indoor allergen.

*74.  Fernandez-Caldas E, Fox R, Trudeau W, Lockey R:
  Allergenicity of the mite, Blomia tropicalis.

*75.  Fox R, Lockey R:
  Treatment of severe, chronic urticaria (SCU) with dapsone.

*76.  Banerji D, Fox R, Seleznick M, Lockey R:
  A controlled trial of oral nalmefene (N) in chronic urticaria (CU) and atopic dermatitis
  (AD).

*77.  Wright D, Nelson R, Ledford D, Lockey R:
  Serum IgE and human immunodeficiency virus (HIV).

*78.  Lind P, Schou C, Lowenstein H, Lockey R:
  Characterization of cockroach extracts and purification of a cross-reacting, acidic
  allergen.

  Responsiveness of lymphocyte beta adrenergic receptors in patients treated with
  ketotifen.

*80.  Robicsek S, Polson JB, Krzanowski J, Lockey RF, Szentivanyi A:
  High pressure liquid chromatography of human T-lymphocyte phosphodiesterases.

*81.  Berman A, Espinoza L, Diaz J, Rolando T, Vasey F, Lockey R,
  Germain B:
  The rheumatological manifestations of human immunodeficiency syndrome (HIV)
  infection.
Autoantibodies in human immunodeficiency syndrome (HIV) infection with
musculoskeletal involvement.

*83. Minor MW, Nelson RP, Wright DN, Lockey RF:
Adult immunization in human immunodeficiency virus (HIV) infection.
XIII International Congress of Allergology and Clinical Immunology
Oct. 16-21, 1988, Montreux, Switzerland.

84. Schou C, Lind P, Fernandez-Caldas E, Lowenstein H, Lockey RF:
Demonstration of cockroach allergen in house dust samples.
European Academy of Allergology and Clinical Immunology Annual Meeting,
Copenhagen, Denmark, June 18-22, 1988.

*85. Fernandez-Caldas E, Trudeau W, Sanchez-Medina M, Cuadros G, Arlian LG,
Vyszenski-Moher DL, Arruda LK, Chapman M, Lockey RF:
Demonstration of allergenic components in extracts of the mite *Blomia tropicalis*.

*86. Wright DN, Ledford DK, Lockey RF:
Systemic allergic reaction to the Tine Test purified protein derivative (PPD).

*87. Bucholtz GA, Trudeau W, Fernandez-Caldas E, Jelks M, Wunderlin R, Lockey RF:
Comparison of Australian pine species, *Casuarina equisetifolia* and *Casuarina
cunninghamiana*.

*88. Aronoff D, Ledford DK, Schou C, Fernandez-Caldas E, Trudeau W,
Lockey RF:
House dust mite and cockroach allergen concentrations in daycare centers.

89. Trudeau W, Fernandez-Caldas E, Fox R, Lockey R:
Mite aeroallergen concentrations before, during and after vacuum cleaning.

Altman R, Love S, Samuels L:
Cetirizine in the treatment of seasonal rhinitis.

*91. Krzanowski J, Watanabe T, Lockey R, Polson J:
Enhanced contractile responses of canine tracheal smooth muscle (CTSM).

*92. Diaz JD, Nelson RP, Lockey RF, Good RA, Day NK:
Systemic lupus erythematosi (SLE) presenting as human immuno-deficiency virus (HIV) infection.
Nelson RP, Wright DN, Russell DH, Ledford DK, Lockey RF, Good RA:  
Serum prolactin levels in patients with human immunodeficiency (HIV) infection.  
Fifth International Conference on AIDS, June 4-9, 1989, Montreal, Canada.

Brooks SM, Fox RW, Spaul W, Fernandez-Caldas E, Lockey RF:  
Host factors for developing symptoms from indoor air pollution.  

Ganguly R, Chmel H, Lockey RF, Park J:  
Vitamin C mediated enhancement of secretory antibody response to viral antigens.  
30th Annual Meeting of the American College of Nutrition,  
Sept. 25-26, 1989, Norfolk, VA.

Schou C, Fernandez-Caldas E, Lockey RF, Lowenstein H:  
Assay for cockroach allergen exposure.  

Sanchez M, Fernandez-Caldas E, Trudeau W, Cuadros G, Lockey RF:  
Prevalence of specific IgE to 5 different mite species in Bogota, Colombia.  

Fernandez-Caldas E, Trudeau W, Fox RW, Bucholtz GA, Lockey RF:  
Comparison of mite specific IgE and total IgE levels in rhinitis and asthma patients.  

Trudeau W, Fernandez-Caldas E, May J, Pratt D, Lockey R:  
Allergenicity of the mite * Chortoglyphus arcuatus*.  

Lockey RF, Turkeltaub PC, Hubbard JM, Olive ES, Bukantz SC:  

Silton RP, Fernandez-Caldas E, Trudeau WL, Lockey RF:  
Allergenicity of the mite, *Aleuroglyphus ovatus*.  

Russell DW, Fernandez-Caldas E, Trudeau WL, Swanson MC, Seleznick MJ, Lockey RF:  
Caffeine, a natural acaricide?  

Fox RW, Lockey RF, Altenburger K, Cohan R, Klotz S:  
Clinical evaluation of the safety and efficacy of astemizole/ pseudoephedrine  
combination in the treatment of fall hayfever.  

Wright DN, Trudeau WL, Fernandez-Caldas E, Bucholtz GA, Jelks ML, Lockey RF:  
Cross-reactivity between white oak (*Quercus alba*) and laurel oak (*Quercus laurifolia*).  

Calderon EG, Fernandez-Caldas E, Lockey RF, Coffey RG:  
Second messenger enzyme abnormalities in leukocytes of atopic subjects.


*116. Garcia-Ibanez R, Fernandez-Caldas E, Garcia-Ramos E, Arango L, Lockey RF:
   Aeroallergen sensitivity in high altitude Guatemala City.

*117. Fernandez-Caldas E, Trudeau WL, Garcia-Ramos E, van Hage-Hamsten M, Johansson SGO, Lockey RF:
   Sensitization to house dust and storage mites in urban dwellers.

*118. Sanchez M, Fernandez-Caldas E, Swanson M, Schou C, Trudeau WL, Garcia-Ramos E, Lockey RF:
   Group I mite allergen concentrations in Bogota, Colombia.

*119. Lockey RF, Garcia-Ramos E, Fernandez-Caldas E, Seleznick M:
   Skin test reactivity and allergic respiratory symptoms in adolescents on a subtropical island.

*120. Puerta L, Fernandez-Caldas E, Caraballo LR, Lockey RF:
   Cross-reactivity among Blomia tropicalis, Lepidoglyphus destructor and Dermatophagoides farinae.

   HIV gene detection in infants and children.

   Allergen-specific IgE levels in children presenting to the emergency room with acute asthma.

*123. Caraballo L, Puerta L, Fernandez-Caldas E, Lockey R:
   Crossreactivity among Aleroglyphus ovatus, Chortoglyphus arcuatus and Dermatophagoides.

*124. Hackney JF, Heim O, Schultze M, Wagner H, Zority J, Lockey RF, Krzanowski J, Szentivanyi A:
   Adrenergic mechanisms in the IL-3 and GM-CSF induced de novo synthesis or histidine decarboxylase in hemopoietic progenitor cells.

*125. Robicsek S, Heim O., Reiner S., Hackney JF, Zority J, Lockey RF, Szentivanyi A:
   Characterization of the A549 B-adrenoceptor (BAR) regulating protein components of lymphocyte conditioned medium(LCM) of IM9 cells.
*126. Szentivanyi A, Schultze M, Heim O, Reiner S, Robicsek S, Zority J, Hackney JF, Lockey RF:
Resolution of the B-adrenoceptor (BAR) regulating activity in A549 lung cells of lymphocyte conditioned medium (LCM) derived from cultured IM9 cells with DEAE ion exchange HPLC.

Fluticasone propionate once daily is as effective as beclomethasone dipropionate twice daily for perennial allergic rhinitis.

*128. Askar ME, Ledford DK, Krzanowski JJ, Lockey RF:
The effect of alpha-glucosidase and N-methyl arginine in murine keratinocyte suspension supernatant-derived relaxing factor.
Southeastern Allergy Association, 10/4/91.

*129. Nelson RP, Price L, DiNicolo R, Halsey A, Day NK, Lockey RF, Good RA:
Polymerase chain reaction (PCR) sensitivity and specificity in infants and children.

*130. Garcia-Ramos E, Fernandez-Caldas E, Seleznick MJ, Lockey RF:
Correlation between a family history of asthma and signs of atopy in adolescents on a subtropical island.
Interasma 91, Funchal, Madeira, Portugal, May, 1991

Mite-specific IgE in pediatric acute asthma.

Adrenergic and histamine receptor concentrations in bone marrow cells (BMC).

*133. Szentivanyi A, Calderon EG, Heim O, Schultze P, Wagner H, Zority J, Lockey RF, Dwornik JJ, Robicsek S:
Cell- and species-specific dissociation in the B-adrenoceptor (BAR) upregulating effects of IL-1α derived from lymphocyte conditioned medium and cortisol.

*134. Askar ME, Ledford DK, Krzanowski JJ, Lockey RF:
Characterization of the molecular weight of the murine keratinocyte suspension supernatant (MKSS) derived bronchial smooth muscle (BSM) relaxing factor.
*135. Robicsek S, Szentivanyi A, Calderon EG, Heim O, Schultze P, Wagner H, Lockey RF, Dwornik JJ:
Concentrated IL-1a derived from human T-lymphocytes binds to a specific single class surface receptor on human bronchial epithelial cells and induces the reduction of B-adrenoceptor (BAR) mRNA via an associated or separate receptor-linked signaling pathway.

*136. Reid MJ, Lockey RF, Turkeltaub P, Platss-Mills TAE, Lehrer SB:
Fatalities from immunotherapy (IT) 1990-91.

*137. Dwornik JJ, Szentiivanyi A, Heim O, Schultze P, Wagner H, Zority J, Calderon EG, Lockey RF:
IL-1a may replace requirement for adrenergic input in the sensitization of bone marrow hemopoietic progenitor cells (BMC) to the IL-3 and GM-CSF induced de novo synthesis of histidine decarboxylase (HDC).

*138. Trudeau W, Fernandez-Caldas E, Lee D, Lockey RF:
Molecular weights and isoelectric points of Blomia tropicalis allergens.

*139. Edwards T, Trudeau W, Fernandez-Caldas E, Lee D, Seleznick MJ, Lockey RF:
Proteinases in storage mite extracts.

*140. Jacinto CM, Fernandez-Caldas E, Trudeau WL, Lockey RF:
Skin test reactivity to Blomia tropicalis in subjects with asthma and/or rhinitis.

*141. Szentivanyi J, Heim O, Schultze P, Wagner H, Calderon EG, Lockey RF, Robicsek S, Szentiivanyi A:
Similarities and differences in patterns of B-adrenergic regulation by lymphocytic proteins in respiratory and cutaneous atopy versus cystic fibrosis.

*142. Nelson RP, Price LJ, Halsey AB, Lockey RF, Good RA:
HIV gene detection in infants and children.

*143. Fernandez-Caldas E, Mercado R, Puerta L, Lockey RF, Carballo LR:
House dust mite sensitivity and mite fauna in the tropics.

*144. Puerta L, Fernandez-Caldas E, Mercado D, Lockey RF, Carballo LR:
Blomia Tropicalis, Der p I and Der f I allergen levels in house dust samples in Cartagena, Colombia.


*172. Fernandez-Caldas E, Naspitz CM, Rizzo CM, Lockey RF, Sole D, Mimica T: Mite allergen and endotoxin levels in mattress and floor dust samples in Sao Paulo, Brazil. The International Association of Allergology and Clinical Immunology and the European Academy of Allergology and Clinical Immunology 1994 Meeting, Stockholm, Sweden, June 26 - July 1, 1994.


*176. Bodman S, Gross G, Lockey RF, Mansfield L, Prenner B:
Sodium cromoglycate 10 mg. four times daily: an effective treatment for adult asthmatics.
Submitted to the 1994 European Respiratory Society.

*177. Patino CM, Fernandez-Caldas E, Yanez A, Neffen H, Arlian LG, Lockey RF, Baena-Cagnani CE:


179. Codina R, Morell F, Rodrigo MJ, Fernandez-Caldas E, Trudeau WL, Lockey RF:
Stability studies of soybean hull extracts.
University of South Florida Health Sciences Center. Faculty and Students Research Day. Tampa, FL, October 1994.

*180. Kemp SF, Fernandez-Caldas E, Lockey RF, Stanaland BE, Arlian LG:
Skin test reactivity to Euroglyphus Maynei in Florida: A comparison with three other house dust mite species.

*181. Puerta L, Carballo LR, Fernandez-Caldas E, Avjioglu A, Marsh D, Lockey RF, Dao ML:
Nucleotide sequence of a cDNA coding for a Blomia Tropicalis allergen.

182. Codina R, Morell F, Rodrigo MJ, Fernandez-Caldas E, Trudeau WL, Lockey RF:
Stability studies of soybean hull extracts.
51st Annual Meeting of the American Academy of Allergy and Clinical Immunology, New York, February 1995.

*183. Naspitz CK, Rizzo MC, Fernandez-Caldas E, Mimica I, Lockey RF:
The role of der p I intradomiciliar exposure on clinical severity of asthma, in Sao Paulo, Brazil.

*184. Stanaland BE, Fernandez-Caldas E, Kemp SF, Brenner R, Lockey RF:
Nasal Provocation with cat flea, Ctenocephalides Felis, extract.

*185. Rizzo MC, Naspitz CK, Sole D, Fernandez-Caldas E, Mimica I, Lockey RF:
Clinical evaluation of asthmatic patients exposed to different levels of intradomiciliar endotoxin (et), in Sao Paulo, Brazil.
*186.  Lockey RF, Lavins BJ, Snader L:
Effects of 13 weeks of treatment with ICI 204,219 (AccolateTM) in patients with mild to moderate asthma.

*187.  Puerta L, Caraballo LR, Fernandez-Caldas E, Lockey RF, Dao M:
Expression of a Recombinant *Blomia tropica*lis Allergen. XVI European Congress of Allergology and Clinical Immunology, European Journal of Allergy and Clinical Immunology, Supplement No. 26, 50:134, 1995.

*188.  Baena-Caganani C, Fernandez-Caldas E, Patino C, Cuello M, Arlian LG, Codina R, Lockey RF:
Sensitization to Domestic Mites and Cross-Reactivity Studies in Argentina. XVI European Congress of Allergology and Clinical Immunology, European Journal of Allergy and Clinical Immunology, Supplement No. 26, 50:72, 1995.

Der p 1, Der f 1 Allergen Levels and Mold Counts in Homes of Asthmatic vs. Non-Asthmatic Children. XVI European Congress of Allergology and Clinical Immunology, European Journal of Allergy and Clinical Immunology, Supplement No. 26, 50:73, 1995.

Double-Blind Placebo controlled Trial of Ipratropium Bromide (IB) Nasal Spray 0.06% and 0.12% in the Treatment of Allergic Perennial Rhinitis (APR) XVI European Congress of Allergology and Clinical Immunology, European Journal of Allergy and Clinical Immunology, Supplement No. 26, 50:67, 1995.

*191.  Codina R, Morell F, Rodrigo M, Fernandez-Caldas E, Trudeau W, Lockey RF:
Specific IgG to Soybean Hull Allergens in Soybean Asthma.

*192.  Lockey RF, Lavins BJ, Snader L:

*193.  Kemp S, Fernandez-Caldas E, Lockey RF, Stanaland B, Arlian L:

*194.  Kemp SF, Lockey RF, Wolf BL, Lieberman P:


203. Codina R, Arlian LG, Fernandez-Caldas E, Patino C, Gurne SE, Lockey RF, Baena-Cagnani CE:
Sensitization to house dust mites in asthmatic children in Argentina and cross-reactivity studies.

*204. Bukantz SC, Calderon E, Lockey RF:
Assay of ABO(H) Erythrocyte Antigen by Hemagglutination Inhibition of Murine Monoclonal AntiA and AntiB Antibodies.
American Academy of Allergy, Asthma and Immunology 52nd Annual Meeting, New Orleans, Louisiana, March 15-20, 1996.

*205. Kemp SF, Lockey RF:
Peanut Anaphylaxis: An Allergist-Immunologist's Personal Experience with Food Cross-Contamination.
American Academy of Allergy, Asthma and Immunology 52nd Annual Meeting, New Orleans, Louisiana, March 15-20, 1996.

*206. Swank RL, Lockey RF, Hernandez LS, Coughlin JP:
Fire Ant Induced Skin Tissue Loss and Infection in a Nine Month Old Child.
American Academy of Allergy, Asthma and Immunology 52nd Annual Meeting, New Orleans, Louisiana, March 15-20, 1996.

207. Predolini N, Araoz J, Fernandez-Caldas E, Codina R, Lockey RF, Neffen H:
Variacion anual de los alergenos derivados de acaros (Grupo I) en Santa Fe, Argentina (Seasonal variation of group 1 mite allergens). XII Congreso Latinoamericano de Alergia e Inmunologia.

Quantitative RNA Levels Before and After Influenza Immunization in HIV-Infected Adults.
XIth International Conference on AIDS, Vancouver, British Columbia, July 7-12, 1996.

209. Chandra S, Lockey RF, Alidina LW, Beal D, Codina R, Gehring K:
Adverse health effects and elimination of dust mites in humid climate housing.

*210. Lockey RF, Codina R, Oehling AG, Arduoso LRF, Crisci CD, Bertoya NHL:
Prevalence of specific IgE and IgG4 in a rural population exposed to soybean dust in Argentina.
Oehling AG, Codina R, Lockey RF:
Neoallergens as a possible cause of soybean-induced asthma.

Fernandez-Caldas E, Trudeau WL, Ledford DK, Lockey RF:
How useful are room dehumidifiers to control mite allergen levels in bedroom carpets in a subtropical city?

Bukantz SC, Calderon E, Leparc G, Lockey RF:
Human Anti-A and Anti-B iso Antibodies may be produced by Genetically Appropriate Responses to a Constant Endogenous Source of Blood Group Antigens in Mucus.

Ardusso LRF, Fernandez-Caldas E, Crisci CD, Ardusso DD, Lockey RF, Procopio N, Munoz E, Galimany J, Marcipar A, Celentano O, Vacirca AI, Bertoya NH:
Sensitization to *Blomia tropicalis* in a city of Argentina and its relationship with different clinical and immunological parameters.

Codina R, Lockey RF, Rama R:
Purification and sequencing of the main soybean hull allergen Gly m 2, responsible for the Barcelona asthma outbreaks.

Codina R, Lockey RF:
Aerobiologic Survey of the Tampa Bay Area, FL, USA, During 1996.

Chandra S, Parker D, Beal D, Lockey RF, Gehring K:
Eliminating dust mites in new homes through dehumidification.
Submitted for presentation, June 1997 ASHRAE meeting, Boston, MA.

Bukantz SC, Calderon E, Leparc G, Zhang J, Lockey RF:
*219. Rosenbach KP, Ledford DK, Lockey RF:
Long-term use of Budesonide Turbuhaler on Steroid Dependent Asthmatics.
XVIth International Congress of Allergology and Clinical Immunology Cancun, Mexico, October 19-24, 1997.

220. Chandra S, Beal D, Lockey RF, Codina R, Orr GW, Astry DW, Alidina LW:
Performance of Health Houses in Warm Humid Climates.

*221. Rosenbach KP, Windom HH, Lockey RF:
XVIth International Congress of Allergology and Clinical Immunology Cancun, Mexico, October 19-24, 1997.

Effects of catecholamine and serotonin neurotoxins and exocitotoxic amino acids on enhanced histamine production induced by rGM-CSF and/or rIL-3.
XVIth International Congress of Allergology and Clinical Immunology Cancun, Mexico, October 19-24, 1997.

223. Chandra S, Beal D, Codina R, Lockey RF:
Mites, mite allergens and interior environmental conditions in several homes in the hot, humid southeastern United States.
Mites, Asthma & Domestic Design Workshop (MADD III), Wellington School of Medicine, New Zealand, November 14 - 16, 1997.

*224. Behera AK, Kasti G, Kumar M, Matsuse H, Lockey RF, Mohapatra SS:
Molecular Alterations Caused by Respiratory Syncytial Virus (RSV) Infection in Bronchial Epithelial Cells: An in vitro Model for Airway Inflammation.

*225. Reichart C, Codina R, Lockey RF, Montgomery T:
Evaluation of Four Fabric Pore Size Pillows (P) as Effective Filters of Dust Mite Allergens.

*226. Kasti GL, Codina R, Ledford DK, Lockey RF:
Mite Contamination of Food Stuffs.
*227. Lockey RF, Codina R, Chandra S, Beal D:
Reduction of House Dust Mites in Homes Through Whole House
Dehumidification/Ventilation Systems (DVS).
American Academy of Allergy, Asthma and Immunology 54th Annual Meeting,

*228. Thompson M, Shearer D, Lockey R, Fox R, Ledford D:
Systemic Reactions to Percutaneous (P) and Intradermal (ID) Skin Tests (ST).
American Academy of Allergy, Asthma and Immunology 54th Annual Meeting,

*229. Matsuse H, Behera AK, Kumar M, Lockey RF, Mohapatra SS:
In Vivo Cytokine Expression in Murine Lung and Spleen by Respiratory Syncytial
Virus and/or Dust Mite Allergens.
American Academy of Allergy, Asthma and Immunology 54th Annual Meeting,

*230. Kumar M, Behera, AK, Matsuse H, Lockey RF, Mohapatra SS:
Development of BCG Based Allergy Vaccines: A Shuttle Plasmid Vector that Allows
Production and Secretion of Antigens.
American Academy of Allergy, Asthma and Immunology 54th Annual Meeting,

*231. Rosenbach KP, Windom HH, Lockey RF:
American Academy of Allergy, Asthma and Immunology 54th Annual Meeting,

*232. Fox RW, Codina R, Lockey RF:
Possible Role of Molds as Secondary Etiologic Agents of the Asthma Epidemics in
Barcelona, Spain.
American Academy of Allergy, Asthma and Immunology 54th Annual Meeting,

*233. Codina R, Lockey RF, Arduoso L:
Soybean Hull Allergens Induced by Heating and Storage American Academy of
Allergy, Asthma and Immunology 54th Annual Meeting, Washington, D.C., March

*234. Arduoso LRF, Crisci CD, Codina R, Lockey RF, Galimany J, Marcipar A,
Massara A, Strass M, Beroya NHI, Arduoso DD, Medina I, Trojavichich M,
Vinuesa M, Monje S:
Prevalence of sensitization to soybean hulls in subjects with asthma and/or rhinitis
from the south of Santa Fe and northeast of Buenos Aires.
XXII Annual Meeting of the Argentinian Allergy and Immunology Society:
Advances in Allergy, Asthma and Immunology, Buenos Aires, Argentina, August 15-
18, 1998.
*235. Kumar M, Behera AK, Matsuse H, Lockey RF, Mohapatra SS:
   An IFN-γ Plasmid DNA Vaccine Protects BALB/c Mice Against Respiratory Syncytial Virus Infection.

*236. Lockey RF, Codina R:
   Mite Infestation in the Same Florida Home in Rooms with Or without Dogs.

*237. Matsuse H, Hu X, Lockey RF, Wolf S Mohapatra SS:
   IL-12 Enhances the Shift from TH2 to TH1-like response in Mouse Model of Grass Allergy.

*238. Ardusso L, Codina R, Crisci CD, Lockey RF, Bertoya N:
   Prevalence of a Positive Skin test (ST) to Soybean Hull (SH) Allergens in Subjects from Argentina with Asthma and/or Allergic Rhinitis (A-AR) Exposed to Soybean Dust Inhalation (SDI)

*239. Reichart CA, Lockey RF:
   Treatment of Post Viral Cough with Inhaled Beclomethasone (IB).

*240. Codina R, Lockey RF, Ardusso L, Crisci CD, Bertoya N:
   Prevalence of Specific IgE and IgG4 to Soybean Hull (SH) Allergens in Subjects from Argentina with Asthma and/or Allergic Rhinitis (A-AR) Exposed to Soybean Dust Inhalation (SDI).

*241. Matsuse H, Behera AK, Kumar M, Lockey RF, Mohapatra SS:
   The Mechanism of Synergy between Allergic Sensitization and RSV Infection.

*242. Theodoropoulos DS, Lockey RF, Rodriguez JA, Boyce HW, Jr., Johnson M, Ledford DK:
   Upper Respiratory Symptoms in Patients with Gastroesophageal Reflux.


*250. Jaen C, Codina R, Lockey RF:
  Presence of Bla g2 Allergens in Store Purchased Flour Samples.

*251. Codina R, Jaen C, Lockey RF, Arduso L, Crisci C, Bertoya N:
  Increased Allergenicity of Fresh Soybean Hulls After Three Weeks of Storage.

*252. Chandra S, Codina R, Beal D, Lockey RF:
  Dust Mite Allergen Prevention in New Homes in Hot, Humid Climates Using Thorough Vacuum Cleaning and Central Air Conditioning and Dehumidification.

*253. Behera AK, Kumar M, Lockey RF, Mohapatra SS:
  Interferon-y Inhibits Respiratory Syncytial Virus Infection in Hep-2 Epithelial Cells by Upregulation of 2’-5’ Oligoadenylate Cascade.

*254. Lockey RF, Reichmuth D, Codina R, Jaen C:
  Ferret Allergy.

*255. Bukantz SC, Mohapatra SS, Zhang J, Leparc G, Lockey RF:
  Induction of IgE-Specific for Blood Group Antigens.

*256. Kuderer NM, San Juan HG, Kong X, Esch R, Lockey RF, Mohapatra SS:
  Allergen-Induced Production of Interleukin-8 By Human Airway Epithelial Cells Involves Activation of p44/42 Map Kinase.

*257. Mohapatra SS, Lockey RF, Matsuse H, Behera A, Kumar M:
  Recurrent respiratory syncytial virus infection promotes development of asthma.
  XVII International Congress of Allergology and Clinical Immunology, Sydney, Australia, October 15-20, 2000.


*265. Kong X, San Juan H, Kumar M, Lockey RF, Mohapatra SS:
Respiratory syncytial virus-induced early gene expression involves activation of stat 1
Gα and map kinases in A549 epithelial cells.
American Academy of Allergy Asthma and Immunology 57th Annual Meeting, New

*266. Kumar M, Behera AK, Zhang J, Lockey RF, Mohapatra SS, Perez-Dela Cruz C, Lin J, Leong
KW, Huang SK:
A RSV genome chitosan nanosphere (RGCN) vaccine against respiratory syncytial
virus (RSV) infection.
American Academy of Allergy Asthma and Immunology 57th Annual Meeting, New

*267. Behera AK, Kumar M, Lockey RF, Mohapatra SS:
Mechanism of interferon-γ inhibition of respiratory syncytial virus infection of human
epithelial cells.
American Academy of Allergy Asthma and Immunology 57th Annual Meeting, New

*268. King MJ, Luck TW, Reichmuth DA, Crockett RE, Lockey RF:
The effect of age and sun damage on allergy skin test results.
American Academy of Allergy Asthma and Immunology 57th Annual Meeting, New

*269. Crockett RE, Lockey RF:
Anaphylaxis from parenteral thiamine self-administered at home.
American Academy of Allergy Asthma and Immunology 57th Annual Meeting, New

*270. Lockey RF (participating investigator):
Fluticasone Propionate/Salmeterol HFA MDI Has a Rapid Onset of
Effect in Asthmatics Treated with Short-Or Long-Acting Beta2-Agonists (BA) or

*271. Hicks M, Reichmuth D, Lockey RF, Bielsa L, Good R, Day N:
Factor I Complement Deficiency in an Individual of Parents with Normal Factor I.
AAAAI 58th Annual Meeting, New York City, March 1-6, 2002.

*272. Behera AK, Kumar M, Lockey RF, Mohapatra SS:
Mucosal 2’-5’ Oligoadenylate Synthetase (2-5 AS) Gene Transfer Attenuates
Respiratory Syncytial Virus Infection in a Murine Model.

*273. Kumar M, Behera AK, Lockey RF, Mohapatra SS:
Role of Mucosal IFN-Y Gene Transfer on Allergic Sensitization and RSV Infection.


*277. Hicks RM, Reichmuth D, Lockey RF, Bielsa L, Good RA, Day NK: Factor I Complement Deficiency in an Individual of Parents with Normal Factor I. 

*278. Diwadkar R, Codina R, Mobley LL, Lockey RF: Study of the Possible Interference of Disodium Ovtaborate Tetrahydrate (DOT), Carpet Shampoo, and Boric Acid on the Measurement of Der F1 and Der P1 in Dust Samples by ELISA using Monoclonal Antibodies. 


*281. San Juan HG, Lockey RF, Mohapatra SS: Activation of PKC Isozymes in Normal Human Bronchial Epithelial Cells by Respiratory Syncytial Virus Infection. 


Behera AK, Kumar M, Lockey RF, Mohapatra SS:
Adenovirus-mediated IFN-g gene transfer inhibits established allergen-induced inflammation and airway hyperreactivity in BALB/c mice.

Codina R, Diwadkar R, Mobley LL, Lockey RF:
Environmental assay to measure cat flea (*Ctenophalides felis*) antigens in dust samples using polyclonal antibodies.
Indoor Air 2002, the 9th International Conference on Indoor Air Quality and Climate, Monterey, CA, July, 2002.

Lockey RF, Meeves S, Liao Y, Georges G:
Fexofenadine 180 mg and Cetirizine 10 mg Demonstrate a Similar Effect on Total Symptom Score. 59th American Academy of Allergy Asthma & Immunology Meeting in Denver, CO, March 7-12, 2003.

Ardusso LRF, Codina R, Crisci CD, Lockey RF, et al:
Skin Sensitivity to *Aspergillus flavus* in Patients with Soybean Induced Asthma and/or Allergic Rhinitis. 59th American Academy of Allergy Asthma & Immunology Meeting, Denver, CO, March 7-12, 2003.

Hellermann G, Kong X, San Juan H, Lockey RF, Mohapatra SS:
59th American Academy of Allergy Asthma & Immunology Meeting, Denver, CO, March 7-12, 2003.

King MJ, Bukantz S, Phillips S, Mohapatra SS, Randall TS, Lockey RF:
Serum Total IgE and Specific IgE to *D. pteronyssinus*, but not Eosinophilic Cationic Protein (ECP), Are More Likely to be Elevated in Elderly Asthmatics.
59th American Academy of Allergy Asthma & Immunology Meeting, Denver, CO, March 7-12, 2003.

Mohapatra SS, Kumar M, Behera A, Hellermann G, Lockey RF, Vesely D:
Intranasal Atrial Natriuretic Peptide (ANP) Gene Transfer Attenuates Airway Reactivity in a Mouse Model of Allergic Asthma
59th American Academy of Allergy Asthma & Immunology Meeting, Denver, CO, March 7-12, 2003.

Kong X, Kumar M, Behera A, Hellermann G, Lockey RF, Mohapatra SS:
Chitosan IFN-gamma-gene Nanoparticle (CIN) Therapy for Allergic Asthma in mice involves STAT4 signaling pathway.
59th American Academy of Allergy, Asthma & Immunology Meeting, Denver, CO, March 7-12, 2003.
292. McKnight S, Fox RW, Crockett RE, Lockey RF:
Anaphylactic Reaction to High Dose Methotrexate with Successful Desensitization. 59th American Academy of Allergy Asthma & Immunology Meeting, Denver, CO, March 7-12, 2003.

293. Schroer B, Lockey RF:

294. Lockey RF, Abreu P, Kimel M, Sacks H:

295. Mohapatra SS, Lockey RF:

296. San Juan Vergara HG, Lockey RF, Mohapatra SS:
*J Allergy Clin Immunol* 2004;113(2):S196. (#681)

*J Allergy Clin Immunol* 2004;113(2):S221. (#781)

298. Kong X, San Juan H, Behera A, Lockey RF, Mohapatra SS:
Cross-Talk Between ERK-1/2 and STAT-1-Alpha Pathways in Respiratory Syncytial Virus-Induced Early Gene Expression in Human Epithelial Cells. 60th American Academy of Allergy Asthma & Immunology Meeting, San Francisco, CA, March 19-23, 2004.
*J Allergy Clin Immunol* 2004;113(2):S265. (#955)

299. Singam RV, Kong X, Hellermann G, San Juan H, Behera S, Zhang W, Jena PK, Lockey RF:
*J Allergy Clin Immunol* 2004;113(2):S325. (#1201)
Inhibition of Respiratory Syncytial Virus Replication by Vector-Derived Small Interfering RNAs Against NS1 Protein.  

Singam R, Ledford D, Lockey RF, Mohapatra SS:  


DeMarco PJ, Codina R, Bagg AS, Fox RW, Lockey RF:  
Indoor levels of fungal spores in Central Florida homes without obvious moisture problems. 61st American Academy of Allergy, Asthma & Immunology Annual Meeting, San Antonio, TX, March 18-22, 2005.  

Zhang W, Yang H, Behera S, Kong X, Lockey RF, Mohapatra SS:  

Kong X, Zhang W, Lockey RF, Auais A, Piedemont G, Mohapatra SS:  
Short interference RNA for RSV-NS1 gene attenuates virus infection in Fischer 344 rats. 61st American Academy of Allergy, Asthma and Immunology Annual Meeting, San Antonio, TX, March 18-22, 2005.  

Bagg AS, Ledford DK, Lockey RF:  
Progesterone associated angioedema and vasculitis. 61st American Academy of Allergy, Asthma and Immunology Annual Meeting in San Antonio, TX, March 18-22, 2005.  
*J Allergy Clin Immunol* 2005; 115(2), S105. #420.

San Juan Vergara H, Cuevas J, Lockey RF, Mohapatra SS:  
Role of calcium in PKC-α activation and RSV infection of normal human bronchial epithelial (NHBE) cells. 61st American Academy of Allergy, Asthma and Immunology Annual Meeting, San Antonio, TX, March 18-22, 2005.  
*J Allergy Clin Immunol* 2005; 115(2), S141, #564.


*316. Ramey JT, Rosenbach KP, Shah M, Ledford DK, Lockey RF:  
Leukocytoclastic Vasculitis and Truncal Erythroderma: two case reports of adverse skin reactions to technetium-99m sestamibi (Tc-99m-S). Florida Allergy, Asthma and Immunology Society (FAAIS) Meeting, Boca Raton, FL, June 10-12, 2005, and American College of Allergy, Asthma and Immunology (ACAAI) Meeting, Anaheim, CA, November 4-9, 2005. 
*Annals of Allergy, Asthma & Immunology* 2006; 96(1):226.

*317. Ramey J, Lockey RF:  
Possible allergic reaction to sublingual and transdermal nitroglycerin. 
*Allergy Asthma Proc* (review article), 2006; 27(3).

*318. Chacko T, Glaum M, Lockey RF:  
Asymptomatic Healthy Adult with Persistent Eosinophilia (1st prize abstract award). 
Florida Allergy, Asthma & Immunology Society annual meeting, Kissimmee, FL, June 8, 2006.

*319. Cole SF, Lockey RF:  
Primary Gastrointestinal Lymphangiectasia Presenting as *Cryptococcus* Meningitis”. 
Florida Allergy, Asthma & Immunology Society annual meeting, Kissimmee, FL, June 8, 2006.

*320. Glaum M, Nimal S, Lockey RF, Mohapatra, SS:  
Atrial Natriuretic Peptide Activates Human Mast Cells via an IgE-Independent Mechanism. Presented at the FOCUS conference (Federation of Clinical Immunology Societies), San Francisco, CA, June 2, 2006.  

*321. Glaum MC, Nimal S, Lockey RF, Mohapatra SS:  
Atrial Natriuretic Peptide is Released from Human Mast Cells following IgE-Mediated Activation. 63rd Annual American Academy of Allergy, Asthma & Immunology Meeting, San Diego, CA, February 23 – 27, 2007.  

*322. Nimal S, Glaum MC, Jena PK, Lockey RF, Mohapatra SS:  

*323. Wang X, Xu W, Kong X, Shirley S, Lockey RF, Mohapatra SS:  

*324. Chacko T, Glaum M, Ledford D, Fox R, Lockey RF:  


Zhang W, Cao X, Hellermann G, Kong X, Chen D, Wang J, Lockey RF, Mohapatra SS:
Mechanism of Atrial Natriuretic Peptide Receptor (NPRA) – Mediated Induction of
Tolerogenic Dendritic Cell (DC).
64th Annual American Academy of Allergy, Asthma & Immunology Meeting,

Shin B, Davis Y, Kong X, Park SJ, Lockey RF, Mohapatra SS:
SiRNA for Intercellular Adhesion Molecule-1 (ICAM-1) Decreases Infection of A549
Cells by Respiratory Syncytial Virus (RSV) and Human Rhinovirus (HRV)-16.
64th Annual American Academy of Allergy, Asthma & Immunology Meeting,

Glaum MC, Liu G, Lockey RF, Mohapatra SS:
Identification of a Stable Human Mast Line Derived from Human Cord Blood Stem
Cells.
64th Annual American Academy of Allergy, Asthma & Immunology Meeting,

Montpetit AJ, Shirley SA, Lockey RF, Mohapatra SS:
Cigarette Smoke Condensate affects Dendritic Cell (DC) Maturation by Modulating
DC-Epithelial Cell Cross-Talk.
64th Annual American Academy of Allergy, Asthma & Immunology Meeting,

Wang J, Zhang W, Wang X, Lockey RF, Mohapatra SS:
Role of MicroRNAs in the Pathogenesis of Asthma.
64th Annual American Academy of Allergy, Asthma & Immunology Meeting,

Kong XY, Hellermann GR, Zhang WD, Jena PK, Kumar M, Behera A, Behera S,
Lockey RF, Mohapatra SS:
Chitosan IFN-Gamma Nanogene (CIN) Therapy for Lung Disease: Modulation of T
Cell and Dendritic Cell Immune Responses.
2008 American Thoracic Society International Conference, Toronto, Canada, May 16-
21, 2008.

Garay SM, Bensch GW, Lockey RF:
Rapid Reduction of Nocturnal Awakenings with Inhaled Mometasone Furoate in
Adults with Mild to Moderate Persistent Asthma.
American Thoracic Society International Conference, Toronto, Canada, May 16-21,
2008.
Phillips JF, Bagg AS, Lockey RF:
Systemic Reactions (SRs) to Subcutaneous Allergen Immunotherapy (SCIT) and the Response to Epinephrine.

Wang J, Zhang W, Li K, Chen D, Liu G, Lockey RF, Mohapatra SS:
Npr1 Deficiency Upregulates Regulatory T Cells (Tregs) Through Impaired Dendritic Cell (DC) Development.

Shin B, Cole SL, Park S, Ledford DK, Lockey RF:
A New Symptom Based Questionnaire for Predicting Asthma.

Glaum MC, Liu G, Lockey RF, Mohapatra SS:
Mediator Release from a New Human Mast Cell Line (USF-MC1).

Kumar A, Vo D, Davis Y, Lockey RF, Mohapatra SS:
A Novel Microfluidic Assay for Detection of Breath Biomarkers.

Boyapalle S, Zhang W, Cao X, Lockey RF, Mohapatra SS:
Nuclear Trafficking and Regulation of Innate Immunity by Respiratory Syncytial Virus (RSV) NS1 protein.

Zhang W, Boyapalle S, Cao X, Wang J, Lockey RF, Mohapatra SS:
RSV NS1 Protein Blocks the IFN Response by Blocking RIG-I Interaction with the Mitochondrial Antiviral Signaling Protein. MAVS.

Kong X, Zhang W, Jena PK, Lockey RF, Mohapatra SS:
Natriuretic Peptide Signaling Pathway Involvement in Respiratory Syncytial Virus Infection of Lung Epithelium.
Glaum MC, Liu G, Wang JW, Lockey RF, Mohapatra SS:
Cytokine mRNA expression and SV40 transfection of a new human mast cell line (USF-MC1).

Kumar A, El-Badri N, Lockey RF, Mohapatra S, Cameron DF:
Sertoli Cell Mediated-Targeted Drug Delivery To The Lungs.

Wang J, Li K, Zhang W, Lockey RF, Mohapatra S, Mohapatra SS:
Over-expression of MiRRA2 in vivo Impairs T Lymphocyte Activation
*J Allergy Clin Immunol* 2010; 125(2): AB76. (#301).

Rael EL, Ramey JT, Lockey RF:
Oxymetazoline (OXY) Hydrochloride Combined with Mometasone Nasal Spray (MNS) for Persistent Nasal Congestion (NC)

Glaum MC, Liu G, Wang J, Lockey RF, Mohapatra SS:
Degranulation, Cytokine mRNA Expression and SV40 Transfection of an SCF-independent Human Mast Cell Line (USF-MC1)

Atrial Natriuretic Peptide Receptor Signaling Plays a Critical Role in Induction of Tolerogenic Dendritic Cells
*J Allergy Clin Immunol* 2010; 125(2): AB227 (# 891).

Butt A, Alkhalil M, Ledford D, Lockey RF:
Methotrexate for Urticarial Vasculitis and Angioedema with Cryoglobulinemia.
Submitted, WAO International Scientific Conference (WISC), December 5 – 8, 2010, Dubai, UAE.

Aljubran SA, Battula KK, Jalali S, Mohapatra S, Lockey RF, Kolliputi N:
Enhancer of Zeste Homolog 2: APivotal Role in Pulmonary Artery Smooth Muscle Cell Proliferation?
*363. Wang J, Li K, Lockey RF, Mohapatra S, Mohapatra SS:  
Sensitive and Specific Universal RT-qPCR Profiling of miRNAs.  

Clinical Outcomes with Recombinant Human C1 Inhibitor in the Repeat Treatment of Acute Attacks of Hereditary Angioedema in North-American Patients.  

*365. Lockey RF:  
Asthma and Comorbidity.  

*366. Lockey RF:  
Asthma in the Elderly.  

367. Talreja N, Culverhouse S, Shearer D, Lockey RF:  
A Case of Idiopathic Recurrent Isolated Orbital Angioedema with Exophthalmos.  
XXII World Allergy Congress, Cancun, Mexico, December 4 – 8, 2011.

368. Butt A, Rashid D, Fox R, Lockey RF:  
Urticaria and Arthralgias in a Nine-Year Old with Recurrent Urinary Tract Infections.  
XXII World Allergy Congress, Cancun, Mexico, December 4 – 8, 2011.  

369. King MJ, Fitzhugh D, Lockey RF:  
Photoaging Attenuates Skin Test Response to Histamine more than Natural Aging.  
XXII World Allergy Congress, Cancun, Mexico, December 4 – 8, 2011.

*370. Aljubran S, Cox R, Tamarapu P, Lockey RF, Kolliputi N:  
Enhancer of Zeste Homolog 2: A Pivotal Role in Pulmonary Artery Smooth Muscle Cell Proliferation.  
XXII World Allergy Congress, Cancun, Mexico, December 4 – 8, 2011.

*371. Nelson A, Parkerson J, Lockey RF, Mohapatra SS, Mohapatra S, Nagaraj S:  
Role of Myeloid Derived Suppressor Cells in Asthma.  
XXII World Allergy Congress, Cancun, Mexico, December 4 – 8, 2011.

*372. Wang J, Li K, Hellermann G, Lockey RF, Mohapatra SS, Mohapatra S:  
Mir-150 Suppresses Lung Inflammation in a Mouse Model of Experimental Asthma.  
XXII World Allergy Congress, Cancun, Mexico, December 4 – 8, 2011.

374. Shearer D, Lockey RF, Fox R, Ledford D, Glaum M: Incidence of Systemic Reactions (SRs) to Prick (P) and Intradermal (ID) Tests, Response to Immediate (“Stat”) Epinephrine IM (epi IM)Dose Vs. BMI, Number of Delayed SRs, and WAO Systemic Reaction Grade. XXII World Allergy Congress, Cancun, Mexico, December 4 – 8, 2011.


*388. Shearer D, Lockey RF:
Epinephrine (E) for Self-Administration: Autoinjectors and Alternatives.
69th Annual American Academy of Allergy, Asthma & Immunology

*389. Cowan G, Talreja N, Ferguson JE, Jelks M, Ledford DK, Lockey RF:
The Effect of Local Temperature, Wind Velocity and Rain On Aerobiology Sampling;
Ten Year Study (2001-2011), Sarasota, Fl.
69th Annual American Academy of Allergy, Asthma & Immunology

*390. Teng M, Fitzhugh DJ, Tran K, Lockey RF, Collins P:
Functional Characterization of A Cis-Acting Temperature Sensitive Mutation From A
Respiratory Syncytial Virus Vaccine Candidate.
69th Annual American Academy of Allergy, Asthma & Immunology

*391. Talreja N, Ledford DK, Lockey RF:
Effect of Inhaled Corticosteroids (ICS) Vs. Inhaled Corticosteroid with Long-Acting
Beta2 Agonists (ICS/LABA) On Asthma Control: Results From National Asthma Survey.
69th Annual American Academy of Allergy, Asthma & Immunology

*392. Ferguson JE, Lockey RF, Glaum MC:
Presumed Type III Hereditary Angioedema Presenting with Recurrent Abdominal
Distention After Estrogen Use.
69th Annual American Academy of Allergy, Asthma & Immunology

*393. Phillips O, Cox RR, Fukumoto J, Fukumoto I, Tamarapu P, Luong T, Lockey RF, Kolliputi N:
Inhibition of IL-1β Mediated Proinflammatory Cytokine Production by
Epigallocatechin Gallate in Human Alveolar Epithelial Cells
69th Annual American Academy of Allergy, Asthma & Immunology

*394. Cox RR, Phillips O, Fukumoto J, Fukumoto I, Tamarapu P, Luong T, Lockey RF,
Kolliputi N:
Resolvin D1 Inhibits IL-1beta Induced Alveolar Epithelial Cell Activation
69th Annual American Academy of Allergy, Asthma & Immunology
*395. Fukumoto J, Fukumoto I, Huynh B, Cox RR, Parthasarathy PT, Ramanathan GK, Venugopal RB, Lockey RF, Kolliputi N:
NLRP3-Deficient Mice Have an Enhanced Neutrophil Apoptosis and a Suppressed Inflammatory Response to Hyperoxia-Induced Acute Lung Injury.
69th Annual American Academy of Allergy, Asthma & Immunology Meeting, San Antonio, TX, February 22 – 26, 2013.

*396. Talreja N, Cowan GM, Glaum M, Lockey RF:
Lymphopenia Induced by Etanercept.
The American College of Allergy, Asthma and Immunology (ACAAI) 2013 Annual Scientific Meeting, Baltimore, Maryland, November 7 – 11, 2013.

*397. Pepper AN, Westermann-Clark E, Talreja N, Lockey RF:
Radiocontrast Media (RCM) Reactions: Fact versus Fiction.
Poster presentation, American College of Allergy, Asthma and Immunology 2013 Annual meeting, Baltimore, MD, November 7 – 11, 2013.

LRBA Causes Immunodeficiency and autoimmunity by deregulating NFkB-Mediated Multiple Immune Effectors Critical for B Cell Activation.

*399. Pepper A, Westermann-Clark E, Talreja N, Lockey RF:
Radiocontrast Media Reactions: Rectifying Misconceptions about Shellfish Allergy and Iodine “Allergy” in an Academic Institution.

*400. Glaum MC, Rifkin E, Wang JW, Lockey RF, Ledford DK:
Real-Time PCR Quantification of Virginia Live Oak (Quercus virginiana) Pollen.

*401. Livingston L, Cowan G, Lockey RF:
Inhaled Asthma Medications: Highlighting the Differences in Formulations and Use.

*402. Balduzzi M, Updegraff A, Rawson K, Taylor B, King MJ, Lockey RF:
Impulse Oscillometry (IOS) is Easier than Spirometry for Older Asthmatic and Non-Asthmatic Subjects.

*403. Reiser M, Wang JW, Li K, Lockey RF:
LRBA Subcellular Localization: Evidence of the LRBA’s Role in Vesicle Trafficking from the Golgi to Cell Membrane and Endocytosis.


**TAPES:**

1. One hour tape recordings - Medical Sciences Tape Library; Sigma Information, Inc; 545 Cedar Lane; Teaneck, NJ 07666.
2. Series: 
   Lockey RF: Allergic Emergencies
   Lockey RF: Immunopathologic reactions in human disease.
   Lockey RF: Asthma and status asthmaticus.


13. Lockey RF: Participant, "Practical Considerations During Hymenoptera Venom Treatment". A scientific workshop held at the 36th annual meeting, the American Academy of Allergy, February 16, 1986.

14. Lockey RF: Chairman, "Assessment and treatment of allergic disease in the 90's: from allergic rhinitis to immune deficiency". Highlights of a symposium held 11/7/89 at the annual meeting of the Southern Medical Association, Washington, D.C.


16. Lockey RF: “Immunotherapy: Now and in the Future”, Volume XXIV, educations Program (CME) for Current Views in Allergy and Immunology, Current Views Inc., Atlanta, Georgia, May 1996.

17. Lockey RF: “Update on Immunotherapy Vaccines”, Volume XXIX, educational program for Current Views in Allergy and Immunology, Medical College of Georgia, Augusta, Georgia, November 2000.


19. Lockey RF: “Asthma and Comorbidities” Volume 40, Program 4, Current Views in Allergy, Asthma & Immunology, Presented by Medical College of Georgia at Georgia Health Sciences University and Division of Continuing Education, 2012.

20. Lockey RF: Scientific Interviews with Experts, WAO TV, World Allergy Organization, March, 2014:
   - World Allergy Organization Anaphylaxis Guidelines: 2013 Update of the Evidence Base”.
     http://www.youtube.com/watch?v=D2s-6IZy7c
   - Impulse Oscillometry (IOS) is easier than spirometry for older asthmatic and non-asthmatic subjects.
     http://www.youtube.com/watch?v=DOY8p0Q6QVU
   - Radiocontrast media reactions: Rectifying misconceptions about shellfish allergy and iodine “allergy”.
     http://www.youtube.com/watch?v=_hTVW3oc5ZA
NETWORK 
SEGMENTS:

1. Exam Room Network (ERN) Segments, Medical News on:

2. Exam Room Network (ERN) Segments, Medical News:

EXHIBITS:

1. Rhoades R, Buren W, Lockey R, Wittig H:
   The imported fire ant.
   Scientific Exhibit,

2. Rhoades R, Buren W, Lockey R, Wittig H:
   The imported fire ant.
   Florida Medical Association Annual Meeting, May 1974,
   (awarded third prize).

3. The American Academy of Allergy Committee on Insects.
   Monograph on human insect reactions.
<table>
<thead>
<tr>
<th>Title</th>
<th>PI</th>
<th>Date</th>
<th>Status</th>
<th>Sponsor</th>
<th>Funds</th>
<th>IRB #</th>
</tr>
</thead>
<tbody>
<tr>
<td>[protocol no. SARCA] The Study of Acid Reflux in Children with Asthma (SARCA)</td>
<td>Lockey</td>
<td>2009</td>
<td>Closed - PI</td>
<td>American Lung Association</td>
<td></td>
<td>105583</td>
</tr>
<tr>
<td>[protocol no. APR] Asthma Patient Registry</td>
<td>Lockey</td>
<td>09/14/2009</td>
<td>Approved, Open</td>
<td>American Lung Association</td>
<td></td>
<td>108273</td>
</tr>
<tr>
<td>Repeated Nasal Challenge in Skin Prick-Puncture Negative, Intradermal Positive Dust Mite Allergic Rhinitis Patients</td>
<td>Lockey</td>
<td>01/03/2008</td>
<td>Approved, Open</td>
<td>Division Sponsored</td>
<td></td>
<td>00007478</td>
</tr>
<tr>
<td>[protocol no. SOYA] The Study of Soy Isoflavones in Asthma</td>
<td>Lockey</td>
<td>2010</td>
<td>Approved, Open</td>
<td>American Lung Association</td>
<td></td>
<td>Pro00000006</td>
</tr>
<tr>
<td>[protocol no. LASST] Long Acting Beta Agonist Stepdown Study (LASST)</td>
<td>Lockey</td>
<td>Pending</td>
<td>American Lung Association</td>
<td>Division Sponsored</td>
<td></td>
<td>Pro00006255</td>
</tr>
<tr>
<td>Calcium Intake in Children on Inhaled or Intranasal Corticosteroids</td>
<td>Lockey</td>
<td>Submission review in progress</td>
<td>Pending</td>
<td>Division Sponsored</td>
<td></td>
<td>Pro00006255</td>
</tr>
<tr>
<td>Obesity &amp; Asthma: Genetics and Nutrigenetic Response to Omega-3 Fatty Acids</td>
<td>Lockey</td>
<td>01/10/2012</td>
<td>Approved, Open</td>
<td>National Institute of Health</td>
<td></td>
<td>Pro00006491</td>
</tr>
<tr>
<td>Effect of Oxymetazoline Hydrochloride in Combination with Nasal Glucocorticoid on the Apnea Hypopnea Index (AHI), nocturnal oxyhemoglobin saturation, snoring, and sleep quality in Subjects with Persistent Nasal Congestion.</td>
<td>Lockey</td>
<td>05/23/2011</td>
<td>Approved, Open</td>
<td>Division Sponsored</td>
<td></td>
<td>Pro00001844</td>
</tr>
<tr>
<td>Identification of Plasma miRNAs as Potential Biomarkers in Asthma exacerbation</td>
<td>Lockey</td>
<td>08/09/2011</td>
<td>Approved, Open</td>
<td>Division Sponsored</td>
<td></td>
<td>Pro00005011</td>
</tr>
<tr>
<td>Study Title</td>
<td>Investigator</td>
<td>Start Date</td>
<td>Status</td>
<td>Sponsorship</td>
<td>Protocol Number</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td>Myeloid Suppressors in Inflammation</td>
<td>Lockey</td>
<td>9/18/2012</td>
<td>Closed- PI</td>
<td>Division Sponsored</td>
<td>Pro00001787</td>
<td></td>
</tr>
<tr>
<td>Procalcitonin Level as a Diagnostic Aid in Acute Bacterial Sinusitis</td>
<td>Lockey</td>
<td>4/2/2012</td>
<td>Closed - PI</td>
<td>Division Sponsored</td>
<td>106936</td>
<td></td>
</tr>
<tr>
<td>[protocol no. PO4230] A Randomized, 26-Week, Placebo-Controlled Efficacy and Safety Study with a 26-week Long Term Safety Extension, of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared with Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects with Moderate to Severe COPD</td>
<td>Lockey</td>
<td>11/17/2011</td>
<td>Closed - PI</td>
<td>Schering-Plough Corporation</td>
<td>105348</td>
<td></td>
</tr>
<tr>
<td>Oxymetazoline Hydrochloride in Combination with Nasal Glucocorticosteroid for Perennial Allergic and Non-Allergic Rhinitis in Subjects with Persistent Nasal Congestion</td>
<td>Lockey</td>
<td>2/1/2011</td>
<td>Closed - PI</td>
<td>Division Sponsored</td>
<td>102621</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Sponsor</td>
<td>Status</td>
<td>Date</td>
<td>PI Name</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>-----------------</td>
<td>---------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>MK 0476-377</td>
<td>A Double-Blind, Placebo-Controlled, Multicenter, Crossover Study to Evaluate the Effects of a Single Oral Dose of Montelukast, Compared with Placebo, on Exercise-Induced Bronchoconstriction (EIB) in Pediatric Patients Aged 4 to 14 Years</td>
<td>Merck &amp; Company, Inc.</td>
<td>Closed - PI</td>
<td>12/15/2010</td>
<td>Lockey</td>
<td></td>
</tr>
<tr>
<td>PGX003</td>
<td>A Phase I, Randomized Crossover, Double-Blind, Placebo-Controlled Pilot Study Evaluating the Safety of Apadenoson Use in Subjects with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</td>
<td>PGxHealth, LLC</td>
<td>Closed - PI</td>
<td>7/5/2010</td>
<td>Lockey</td>
<td></td>
</tr>
<tr>
<td>PGX002</td>
<td>A Phase I, Randomized Crossover, Double-Blind, Placebo-Controlled Pilot Study Evaluating the Safety of Apadenoson Use in Subjects with Mild to Moderate Asthma</td>
<td>PGxHealth, LLC</td>
<td>Closed - PI</td>
<td>7/5/2010</td>
<td>Lockey</td>
<td></td>
</tr>
<tr>
<td>MeCIS</td>
<td>Methacholine Bronchoprovocation - Influence of High Potency Inhaled Corticosteroids in Asthma (MeCIS)</td>
<td>American Lung Association</td>
<td>Closed - PI</td>
<td>6/8/2010</td>
<td>Lockey</td>
<td></td>
</tr>
<tr>
<td>QAB149B2349</td>
<td>A 12 Week Treatment, Multi-Center, Randomized, Parallel Group, Double Blind, Double Dummy Study to Assess the Superiority of Indacaterol (150 ug o.d.) via a SDDPI in Patients with Moderate to Severe COPD, using Salmeterol (50 ug b.i.d.) as an Active Comparator Delivered via a DISKUS Inhaler</td>
<td>Novartis Pharmaceutical Corporation</td>
<td>Closed - PI</td>
<td>1/19/2010</td>
<td>Lockey</td>
<td></td>
</tr>
<tr>
<td>MK-0633-007</td>
<td>A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group, Dose-Ranging Study of MK-0633 in Adult Patients with Chronic Asthma</td>
<td>Merck &amp; Company, Inc.</td>
<td>Closed - PI</td>
<td>1/4/2010</td>
<td>Lockey</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Title</td>
<td>Principal Investigator</td>
<td>Start Date</td>
<td>Status</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------</td>
<td>------------</td>
<td>--------------</td>
<td>----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>ADC111891</td>
<td>An Evaluation of Lung Function and Symptoms in Patients with Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy</td>
<td>Lockey</td>
<td>11/7/2009</td>
<td>Closed - PI</td>
<td>GlaxoSmithKline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Naturalistic Studies of Parental Permission and Assent for Research</td>
<td>Lockey</td>
<td>10/27/2009</td>
<td>Closed - PI</td>
<td>Nemours Foundation</td>
<td></td>
</tr>
<tr>
<td>MK-0633-007 Extension</td>
<td>A Double-Blind, Placebo-Controlled Extension to the Study of MK-0633 in Adult Patients with Chronic Asthma (Extension to Protocol 007)</td>
<td>Lockey</td>
<td>10/20/2009</td>
<td>Closed - PI</td>
<td>Merck &amp; Company, Inc.</td>
<td></td>
</tr>
<tr>
<td>CQAB149B2335S</td>
<td>A 26-Week Treatment, Multicenter, Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected from 75, 150, 300 &amp; 600 ug o.d.) in Patients with Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 ug b.i.d.) and Open Label Tiotropium (18 ug o.d.) as Active Controls CQAB149B2335S</td>
<td>Lockey</td>
<td>5/4/2009</td>
<td>Closed - PI</td>
<td>Novartis Foundation</td>
<td></td>
</tr>
<tr>
<td>PO4705</td>
<td>A 52-Week Efficacy and Safety Non-Interiority Study of Fluticasone Propionate/Salmeterol 250/50 mcg BID Delivered by Dry Powder Inhaler (Diskus) Versus Mometasone Furoate/Formoterol Fumerate 200/10 mcg BID Delivered by Pressurized Metered-Dose Inhaler in Persistent Asthmatics Previously Treated with Medium Doses of Inhaled Glucocorticosteroids PO4705</td>
<td>Lockey</td>
<td>4/27/2009</td>
<td>Closed - PI</td>
<td>Schering-Plough Corporation</td>
<td></td>
</tr>
<tr>
<td>Study Title</td>
<td>Author</td>
<td>Start Date</td>
<td>Status</td>
<td>Sponsor</td>
<td>Protocol No.</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>--------</td>
<td>------------</td>
<td>---------------</td>
<td>------------------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Topical Antibiotic Use in Chronic Rhinosinusitis, a Double-Blinded,</td>
<td>Lockey</td>
<td>4/27/2009</td>
<td>Closed - Expired</td>
<td>USF Asthma, Allergy &amp;</td>
<td>106811</td>
<td></td>
</tr>
<tr>
<td>Randomized, Placebo Controlled Study</td>
<td></td>
<td></td>
<td></td>
<td>Immunology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Altana Pharma [protocol no. BY217/M2-124]</td>
<td>Lockey</td>
<td>3/10/2009</td>
<td>Closed - PI</td>
<td>Altana Pharma</td>
<td>104723</td>
<td></td>
</tr>
<tr>
<td>Effect of roflumilast on exacerbation rate in patients with COPD. A 52-week, double-blind study with 500 mcg roflumilast once daily versus placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. ADA109057]</td>
<td>Lockey</td>
<td>3/2/2009</td>
<td>Closed - PI</td>
<td>Glaxo SmithKline</td>
<td>105618</td>
<td></td>
</tr>
<tr>
<td>A 52-Week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. SKY2028-3-004]</td>
<td>Lockey</td>
<td>11/24/2008</td>
<td>Closed - PI</td>
<td>Skye Pharma, Inc.</td>
<td>105273</td>
<td></td>
</tr>
<tr>
<td>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Stratified, Multi-Center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (Flutiform 100/10ug or 250/10ug twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Placebo or Fluticasone (250ug twice daily) and Formoterol (10ug twice daily) Alone in Adolescent and Adult Patients with Moderate to Severe Asthma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Association of Atrial Natriuretic Peptide Gene Polymorphism and Asthma Severity</td>
<td>Lockey</td>
<td>9/22/2008</td>
<td>Closed - PI</td>
<td>Division Sponsored</td>
<td>105901</td>
<td></td>
</tr>
<tr>
<td>A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects with Refractory Asthma, Protocol M05-757</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predicting the Diagnosis of Asthma Based on History</td>
<td>Lockey</td>
<td>6/30/2008</td>
<td>Closed - PI</td>
<td>Division Sponsored</td>
<td>104847</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Investigator</td>
<td>Status</td>
<td>Sponsor</td>
<td>PI</td>
<td>Study ID</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-------------</td>
<td>-----------------------------</td>
<td>---------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>CIGE025AUS23</td>
<td>A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of Xolair (omalizumab) on A 26-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of Xolair (omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients with at Least Moderate Persistent Allergic Asthma Inadequately Controlled with Inhaled Corticosteroids - CIGE025AUS23</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>Novartis Pharmaceutical Corporation</td>
<td>Novartis Pharmaceutical Corporation</td>
<td>104336</td>
</tr>
<tr>
<td>OPL104226</td>
<td>The Use of Topical Antibiotics in Chronic Rhinosinusitis</td>
<td>Lockey</td>
<td>Closed - Expired</td>
<td>Division Sponsored</td>
<td>Division Sponsored</td>
<td>104174</td>
</tr>
<tr>
<td>SLIT03-04</td>
<td>Safety and Dosing Study for Sublingual-Oral Administration of Standardized Glycerinated Cat Hair Allergenic Extract - SLIT03-04</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>GlaxoSmithKline</td>
<td>GlaxoSmithKline</td>
<td>103315</td>
</tr>
<tr>
<td>SB207499, CIL103657</td>
<td>A Randomized, 24-week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD)</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>GlaxoSmithKline</td>
<td>GlaxoSmithKline</td>
<td>103129</td>
</tr>
<tr>
<td>SIRNA</td>
<td>Sinusitis and Rhinitis in Asthma (SIRNA)</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>American Lung Association</td>
<td>American Lung Association</td>
<td>104152</td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Investigator</td>
<td>Start Date</td>
<td>Sponsor</td>
<td>Sponsor Code</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-------------</td>
<td>------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>SFA 100062</td>
<td>A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at Least 12 Years of Age, with Persistent Asthma, Who Have Either a B16-Arg/Arg, a B16-Gly/Gly or a B-16 Arg/Gly Genotype and are Treated with Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg or Salmeterol DISKUS 50 mcg BID - SFA100062</td>
<td>Lockey</td>
<td>11/6/2006</td>
<td>GlaxoSmithKline</td>
<td>103081</td>
<td></td>
</tr>
<tr>
<td>TAPE</td>
<td>Determination of a Specific Phenotype for Asthma and Allergy</td>
<td>Lockey</td>
<td>11/6/2006</td>
<td>Division Sponsored</td>
<td>4573</td>
<td></td>
</tr>
<tr>
<td>TAPE</td>
<td>Effect of Education and Drug Presentation on Efficacy of Montelukast and Placebo in Asthma (TAPE)</td>
<td>Lockey</td>
<td>11/2/2006</td>
<td>National Institutes of Health/DHHS</td>
<td>101072</td>
<td></td>
</tr>
<tr>
<td>DX-88/5 EDEMA 2</td>
<td>An Open Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (recombinant plasma kallikrein inhibitor) in Patients with Hereditary Angioedema - DX-88/5</td>
<td>Lockey</td>
<td>9/25/2006</td>
<td>Dyax Corp.</td>
<td>101852</td>
<td></td>
</tr>
<tr>
<td>SCO40043</td>
<td>A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50mcg BID with Salmeterol DISKUS 50 mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)</td>
<td>Lockey</td>
<td>9/11/2006</td>
<td>GlaxoSmithKline</td>
<td>102880</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Impact of an Asthma Camp on Knowledge and Clinical Outcomes</td>
<td>Lockey</td>
<td>6/22/2006</td>
<td>Division Sponsored</td>
<td>103753</td>
<td></td>
</tr>
<tr>
<td>DX-88/4</td>
<td>An Ascending Four Dose Placebo Controlled Study to Assess the Efficacy and Tolerability of DX-88 (Recombinant Plasma Kallikrein Inhibitor) Administered Following Onset of Acute Attacks of Hereditary Angioedema</td>
<td>Lockey</td>
<td>2/21/2005</td>
<td>Dyax Corp.</td>
<td>100778</td>
<td></td>
</tr>
<tr>
<td>Study Title</td>
<td>PI</td>
<td>Study Date</td>
<td>Sponsor/Investigator</td>
<td>Study Number</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>--------------</td>
<td>------------------------------</td>
<td>--------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effect of Aging and the Effect of Sun Damage on Allergy Skin Tests</td>
<td>Lockey</td>
<td>2/15/2005</td>
<td>Closed - PI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group</td>
<td>Lockey</td>
<td>1/31/2005</td>
<td>Closed - PI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study of the Effects of Ciclesonide HFA-MDI 640 uG/Day and Beclomethasone</td>
<td>Lockey</td>
<td>1/24/2005</td>
<td>Closed - PI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFA-MDI 640 uG/Day on Lens Opacification in Adult Subjects with Moderate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>to Severe Persistent Asthma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Multi-Center, Randomized, Double-Blind, Parallel Group, 40-Week</td>
<td>Lockey</td>
<td>1/11/2005</td>
<td>Closed - PI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comparison of Asthma Control Using Bronchial Hyperresponsiveness As An</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional Guide to Long-Term Treatment in Adolescents and Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receiving Either Fluticasone Propionate/Salmeterol Diskus Bid or</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluticasone Propionate Diskus Bid (or Placebo Bid if Asymptomatic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. SAM 40065]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm, Dose Comparison study of the Efficacy and Safety of Oral 25mg, 50mg,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75mg OPC-6535 and Placebo in the Treatment of Patients with Chronic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obstructive Pulmonary Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. 197-01-210]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Phase II, Multicenter, Randomized, Double-Blind, Placebo-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controlled, Parallel-Arm, Dose Comparison study of the Efficacy and</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety of ONO-6126 in Patients with Chronic, Obstructive Pulmonary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease (COPD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. ONO-6126POU011]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Four Week, Double Blind, Placebo-Controlled, Exploratory Evaluation of</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1.0 Changes and Safety of ONO-6126 in Patients with Chronic, Obstructive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. ANC-MD-17]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Double Blind Study of the Efficacy, Safety, and Pharmacoeconomics of</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flunisolide HFA Inhaler System as Compared to Fluticasone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhalation Aerosol in Patients with Asthma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Investigator</td>
<td>Start Date</td>
<td>Study Status</td>
<td>Sponsor</td>
<td>NCT Number</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>--------------</td>
<td>------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Q2196N</td>
<td>An Observational Study of the Epidemiology and Natural History of Asthma:</td>
<td>Lockey</td>
<td>9/2/2004</td>
<td>Closed - PI</td>
<td>Genentech, Inc.</td>
<td>6063</td>
</tr>
<tr>
<td></td>
<td>Outcomes and Treatment Regimens (Tenor)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parietaria Floridana and Allergic Rhinitis in the Tampa Bay Area</td>
<td>Lockey</td>
<td>3/9/2004</td>
<td>Closed - PI</td>
<td>Division Sponsored</td>
<td>5786</td>
</tr>
<tr>
<td></td>
<td>International Study of Asthma and Allergies in Childhood (ISAAC), Data from</td>
<td>Lockey</td>
<td>2/24/2004</td>
<td>Closed - PI</td>
<td>Asthma &amp; Allergy Foundation</td>
<td>101098d</td>
</tr>
<tr>
<td></td>
<td>the West Coast of Florida</td>
<td></td>
<td></td>
<td></td>
<td>of America (Florida)</td>
<td></td>
</tr>
<tr>
<td>MO16455P/3001</td>
<td>A Multicenter, Double-Blind, Randomized, Parallel Groups, Placebo-Controlled</td>
<td>Lockey</td>
<td>1/31/2004</td>
<td>Closed - PI</td>
<td>Aventis</td>
<td>100033</td>
</tr>
<tr>
<td></td>
<td>Study to Assess the Efficacy and Safety of Fexofenadine 120 MG BID in Subjects with Mild to Moderate Persistent Asthma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M016455P-3003</td>
<td>A Multicenter, Open-Label, Randomized, Parallel Groups Study to Assess the Long-Term Safety Performance of Fexofenadine Compared to Montelukast in Subjects with Asthma</td>
<td>Lockey</td>
<td>1/31/2004</td>
<td>Closed - PI</td>
<td>Aventis</td>
<td>100032d</td>
</tr>
<tr>
<td>340-72</td>
<td>Efficacy and Safety of Monetasone Furoate Dry Powder Inhaler in the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)</td>
<td>Lockey</td>
<td>1/31/2004</td>
<td>Closed - PI</td>
<td>Schering-Plough Corporation</td>
<td>5787</td>
</tr>
<tr>
<td>SAS 30028</td>
<td>A Stratified, Randomized, Double-Blind, Parallel-Group, Multi-Center, 96-Week Study Evaluating the Growth Effects of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg Twice Daily versus Usual Non-Corticosteriod Maintenance Therapy in Pre-Pubescent Pediatric Subjects with Asthma</td>
<td>Lockey</td>
<td>1/26/2004</td>
<td>Closed - PI</td>
<td>GlaxoSmithKline</td>
<td>101073</td>
</tr>
<tr>
<td>016-00</td>
<td>A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Proof-of-Concept Study of L-000454560 in Patients With COPD</td>
<td>Lockey</td>
<td>12/31/2003</td>
<td>Closed - PI</td>
<td>Merck &amp; Company, Inc.</td>
<td>101086c</td>
</tr>
<tr>
<td>Study Title</td>
<td>Investigator</td>
<td>Status</td>
<td>Sponsor</td>
<td>Protocol No.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>--------------</td>
<td>---------------</td>
<td>--------------------------</td>
<td>--------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 Weeks Treatment with 250ug Roflumilast versus Placebo in Patients with Asthma</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>Altana, Inc.</td>
<td>6529d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Possible Allergenicity of Oak Acorns</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>Division Sponsored</td>
<td>6518d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. SAS40037] A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group, 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS® Combination Product 100/50mcg BID, Fluticasone Propionate DISKUS® 100mcg BID, Salmeterol Xinafoate DISKUS® 50mcg BID, or Oral Motelukast 100mg QD</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>GlaxoSmithKline</td>
<td>6465c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. SAM40066] A Multi-Center, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving Concurrent Open-Label ADVAIR DISKUS 100/50mcg BID</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>GlaxoSmithKline</td>
<td>100577d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. P01861] A Placebo- and Active-Controlled Efficacy and Safety Study of a Once-Daily Fixed Combination Tablet of Desloratadine 5mg / Pseudoephedrine 120mg (SCH 483 [5/120]) in Subjects With Seasonal Allergic Rhinitis</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>Schering-Plough Corporation</td>
<td>100611d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. FAP 30010] A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88MCG BID Versus Placebo in Propellant GR106642X in Pediatric Subjects 4 to 11 Years of Age with Asthma</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>GlaxoSmithKline</td>
<td>6459</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Investigator</td>
<td>Start Date</td>
<td>Status</td>
<td>Sponsor</td>
<td>Protocol No.</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>----------</td>
<td>-----------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>M016455M/3002 (PAR)</td>
<td>A Multicenter, Double-Blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Fexofenadine 120 mg BID, Fexofenadine 240 mg QD, and Placebo in Subjects with Perennial Allergic Rhinitis</td>
<td>Lockey</td>
<td>7/31/2003</td>
<td>Closed - PI</td>
<td>Aventis</td>
<td>100544</td>
</tr>
<tr>
<td>LODO</td>
<td>Effectiveness of Low-Dose Theophylline as Add-On Therapy in the Treatment of Asthma (&quot;The LoDo Trial&quot;)</td>
<td>Lockey</td>
<td>7/31/2003</td>
<td>Closed - PI</td>
<td>American Lung Association</td>
<td>6356d</td>
</tr>
<tr>
<td>SD004-0111</td>
<td>START-Inhaled Steroid Treatment As Regular Therapy in Early Asthma: A Study of the Effect of Early Intervention With Long-Term Inhaled Budesonide (Pulmicort(R) Turbuhaler(R)) in Newly Diagnosed Asthma</td>
<td>Lockey</td>
<td>5/31/2003</td>
<td>Closed - PI</td>
<td>AstraZeneca Ltd.</td>
<td>4362</td>
</tr>
<tr>
<td>309801</td>
<td>A Phase 3 Study to Determine the Efficacy and Safety of Cl-Inhibitor (Human) Vapor Heated, Immuno in Subjects with Hereditary Angioedema (HAE)</td>
<td>Lockey</td>
<td>4/30/2003</td>
<td>Closed - PI</td>
<td>Baxter Healthcare Corporation</td>
<td>5812</td>
</tr>
<tr>
<td>07</td>
<td>A Double Blind, Placebo Controlled, Long Term Growth Study of HFA Flunisolide in Children with Mild Asthma</td>
<td>Lockey</td>
<td>12/31/2002</td>
<td>Closed - PI</td>
<td>Forest Laboratories, Inc.</td>
<td>5707</td>
</tr>
<tr>
<td>ANC-MD-09</td>
<td>Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Once Daily Flunisolide HFA Inhaler System in Patients with Asthma Currently Treated with Inhaled Steroids</td>
<td>Lockey</td>
<td>12/31/2002</td>
<td>Closed - PI</td>
<td>Forest Laboratories, Inc.</td>
<td>6103</td>
</tr>
<tr>
<td>PO1978</td>
<td>Placebo Controlled Efficacy and Safety Study of a Once-Daily PM and Twice Daily Regimens of Mometasone Furoate Administered Via Dry Powder Inhaler in Subjects with Asthma Who Were Previously Maintained on Inhaled Corticosteroids</td>
<td>Lockey</td>
<td>10/31/2002</td>
<td>Closed - PI</td>
<td>Schering-Plough Corporation</td>
<td>6050</td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Sponsor</td>
<td>PI</td>
<td>Status</td>
<td>Enrollments</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>051-915</td>
<td>A Randomized, Double-Blind Study to Determine the Efficacy of Levalbuterol Versus Racemic Albuterol in the Treatment of Acute Asthma</td>
<td>Sepracor, Inc.</td>
<td>Closed - PI</td>
<td>5969</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>051-916</td>
<td>A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 8 Week Comparison of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease</td>
<td>Glaxo Wellcome, Inc.</td>
<td>Closed - PI</td>
<td>5944</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMS40321</td>
<td>[protocol no. SMS40321] A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group comparison of Salmeterol Xinafoate Inhalation Aerosol Versus Ipratropium Bromide and Albuterol Sulfate Inhalation Aerosol in Subjects With Chronic Obstructive Pulmonary Disease</td>
<td>GlaxoSmithKline</td>
<td>Closed - PI</td>
<td>6424</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M016455A/4122</td>
<td>[protocol no. M016455A/4122] A Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Randomized Study of Fexofenadine HCL 180 MG vs. Cetirizine HCL 10 MG in Subjects with Moderate to Severe Seasonal Allergic Rhinitis (SAR) During the Fall or Winter/Spring Allergy Season</td>
<td>Aventis</td>
<td>Closed - PI</td>
<td>6379</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>051-917</td>
<td>A Randomized, Double-Blind, Double Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50 mg BID) via DISKUS® with Oral Montelukast (5 mg QD) Chewable Tablets in Children 6 to 12 Years of Age with Persistent Asthma</td>
<td>Glaxo Wellcome, Inc.</td>
<td>Closed - PI</td>
<td>5921</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>051-918</td>
<td>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) in the Treatment of Viral Respiratory Infection in Children 1 to 6 Years of Age</td>
<td>ViroPharma, Inc.</td>
<td>Closed - PI</td>
<td>6388</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Description</td>
<td>Investigator</td>
<td>Start Date</td>
<td>Status</td>
<td>Sponsor</td>
<td>PI Code</td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>----------</td>
<td>---------------------</td>
<td>---------</td>
</tr>
<tr>
<td>061/059</td>
<td>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) in the Treatment of Viral Respiratory Infection in Children 7 to 12 Years of Age</td>
<td>Lockey</td>
<td>7/31/2002</td>
<td>Closed - PI</td>
<td>ViroPharma, Inc.</td>
<td>6389</td>
</tr>
<tr>
<td>SIIVA</td>
<td>A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of the Safety of Inactivated Influenza Vaccine in Adults and Children with Asthma</td>
<td>Lockey</td>
<td>6/30/2002</td>
<td>Closed - PI</td>
<td>American Lung Association</td>
<td>5853</td>
</tr>
<tr>
<td></td>
<td>Qualitative Interview Regarding Experiences on Bayer 19-8004 Trial</td>
<td>Lockey</td>
<td>5/31/2002</td>
<td>Closed - PI</td>
<td>Bayer Corporation</td>
<td>6290</td>
</tr>
<tr>
<td></td>
<td>The Efficacy of Disodium Octaborate Tetrahydrate (DOT) and Vacuum Cleaning in Lowering House Dust Mite Population and House Dust Mite Allergen Levels in Homes</td>
<td>Lockey</td>
<td>5/31/2002</td>
<td>Closed - PI</td>
<td>Division Sponsored</td>
<td>5841</td>
</tr>
<tr>
<td>M97700-023</td>
<td>A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Dose-Finding Study to Evaluate the Effectiveness of 28 Days of Treatment with LDP-977 in Adult Asthmatics</td>
<td>Lockey</td>
<td>4/30/2002</td>
<td>Closed - PI</td>
<td>Millenium Pharmaceuticals, Inc.</td>
<td>6252</td>
</tr>
<tr>
<td></td>
<td>Rhinitis in Patients with Gastroesophageal Reflux: Prevalence and Characterization</td>
<td>Lockey</td>
<td>4/30/2002</td>
<td>Closed - PI</td>
<td>Division Sponsored</td>
<td>5664</td>
</tr>
<tr>
<td></td>
<td>A Twelve Month, Open Label Study of Oxis™ Turbuhaler® in Adults and Adolescents with Asthma</td>
<td>Lockey</td>
<td>1/31/2002</td>
<td>Closed - PI</td>
<td>AstraZeneca Ltd.</td>
<td>6110</td>
</tr>
<tr>
<td>ADVIL SAR-AD-99-02</td>
<td>Advil Multi-Symptom Allergy Sinus Efficacy and Safety Study</td>
<td>Lockey</td>
<td>1/31/2002</td>
<td>Closed - PI</td>
<td>Whitehall-Robins Healthcare</td>
<td>6111</td>
</tr>
<tr>
<td></td>
<td>A Randomized, Double-Blind, Multicenter Study to Evaluate the Effect of Adding Either Montelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics</td>
<td>Lockey</td>
<td>9/30/2001</td>
<td>Closed - PI</td>
<td>Merck &amp; Company, Inc.</td>
<td>5561</td>
</tr>
<tr>
<td>Study Title</td>
<td>PI Name</td>
<td>Start Date</td>
<td>Status</td>
<td>Sponsor</td>
<td>Protocol No.</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>---------</td>
<td>------------</td>
<td>--------------</td>
<td>------------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>A Phase III, Multicenter, Double-Blind, Parallel Group Study Assessing the Effects of Triamcinolone Acetonide HFA-134A MDI on Growth in Asthmatic Children</td>
<td>Lockey</td>
<td>8/31/2001</td>
<td>Closed-PI</td>
<td>Aventis</td>
<td>5486</td>
<td></td>
</tr>
<tr>
<td>A Multicenter, Randomized, Double-Blind Pilot Study Comparing the Clinical Effect of Intravenous Montelukast with Placebo in Patients with Acute Asthma</td>
<td>Lockey</td>
<td>4/30/2001</td>
<td>Closed-PI</td>
<td>Merck &amp; Company, Inc.</td>
<td>5750</td>
<td></td>
</tr>
<tr>
<td>Melaleuca Tree and Respiratory Disease</td>
<td>Lockey</td>
<td>4/30/2001</td>
<td>Closed-PI</td>
<td>Division Sponsored</td>
<td>5808</td>
<td></td>
</tr>
<tr>
<td>Allergy to Ferret</td>
<td>Lockey</td>
<td>2/28/2001</td>
<td>Closed-PI</td>
<td>Division Sponsored</td>
<td>5562</td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>Investigator</td>
<td>Start Date</td>
<td>Status</td>
<td>Sponsor</td>
<td>Protocol No.</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>----------</td>
<td>----------------------------------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>[protocol no. 0476-074-00 Extension] A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Crossover Study Comparing Combination Montelukast/Loratadine With Montelukast and Loratadine Monotherapies in Patients With Chronic Asthma</td>
<td>Lockey</td>
<td>1/31/2001</td>
<td>Closed - PI</td>
<td>Merck &amp; Company, Inc.</td>
<td>5528</td>
<td></td>
</tr>
<tr>
<td>[protocol no. P00355-18] Efficacy and Safety of SCH 34117 + Pseudoephedrine, BID, vs. its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis</td>
<td>Lockey</td>
<td>9/30/2000</td>
<td>Closed - PI</td>
<td>Schering-Plough Corporation</td>
<td>5475</td>
<td></td>
</tr>
<tr>
<td>Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler (MF-MDI) in the Treatment of Asthma in Children Previously Maintained on Anti-Inflammatory Asthma Medications</td>
<td>Lockey</td>
<td>9/30/2000</td>
<td>Closed - PI</td>
<td>Schering-Plough Corporation</td>
<td>5173</td>
<td></td>
</tr>
<tr>
<td>[protocol no. FLTA 4039] A Randomized, Double-Blind, Parallel Group Comparison Study of Inhaled Fluticasone Propionate (88mcg bid) Versus Montelukast Sodium (10 mg QD) in Subjects Currently Receiving Beta Agonists Alone</td>
<td>Lockey</td>
<td>8/31/2000</td>
<td>Closed - PI</td>
<td>Glaxo Wellcome, Inc.</td>
<td>5145</td>
<td></td>
</tr>
<tr>
<td>[protocol no. SFCA 3006] 1998 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol 50mcg BID and Fluticasone Propionate 500mcg BID Individually and in Combination as Compared to Placebo in COPD Subjects</td>
<td>Lockey</td>
<td>7/31/2000</td>
<td>Closed - PI</td>
<td>Glaxo Wellcome, Inc.</td>
<td>5146</td>
<td></td>
</tr>
<tr>
<td>Biological Standardization: The Quantitative Skin Response in Subjects Skin Tested with Varying Doses of Skin Reactive Substances</td>
<td>Lockey</td>
<td>7/31/2000</td>
<td>Closed - PI</td>
<td>National Institutes of Health/DHHS</td>
<td>5108</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Sponsor</td>
<td>PI</td>
<td>Study Date</td>
<td>Status</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>----</td>
<td>------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>ANC-MD-04-000</td>
<td>A One-Year, Open-Label Study to Evaluate the Safety of HFA Flunisolide in Children with Mild to Moderate Asthma</td>
<td>Forest Laboratories, Inc.</td>
<td></td>
<td>4/30/2000</td>
<td>Closed - PI</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Multicenter, Double-Blind, Randomized Study Comparing a Combination Tablet Containing Montelukast + Loratadine with Inhaled Beclomethasone in Patients with Chronic Asthma</td>
<td>Merck &amp; Company, Inc.</td>
<td></td>
<td>3/31/2000</td>
<td>Closed - PI</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of Salmeterol/Fluticasone Propionate Combination in GR106642X MDI, 50/250mcg BID, and Salmeterol in Propellant 11/12 MDI, 50mcg BID, Fluticasone Propionate in Propellant 11/12 MDI, 250mcg BID, and Placebo in Propellant GR106642X MDI in Adolescent and Adult Subjects with Asthma</td>
<td>Glaxo, Inc.</td>
<td></td>
<td>3/31/2000</td>
<td>Closed - PI</td>
<td></td>
</tr>
<tr>
<td>NKP608</td>
<td>A Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled, Dose-Ranging Trial to Assess the Efficacy and Safety of NKP 608 Microemulsion Capsules in Adult Patients with Chronic Bronchitis</td>
<td>Novartis Pharmaceutical Corporation</td>
<td></td>
<td>10/31/1999</td>
<td>Closed - PI</td>
<td></td>
</tr>
<tr>
<td>Formoterol 056</td>
<td>Randomized, Double-Blind, Between-Patient Trial Comparing Two Doses of Inhaled Formoterol Fumarate Dry Powder (12 and 24 ug b.i.d.) with Placebo and Ipratropium Bromide MDI (40 ug q.i.d.) for 12 Weeks in Patients with Chronic Obstructive Pulmonary Disease, in Terms of Clinical Efficacy, Tolerability and Quality of Life</td>
<td>Novartis Pharmaceutical Corporation</td>
<td></td>
<td>9/30/1999</td>
<td>Closed - PI</td>
<td></td>
</tr>
<tr>
<td>Study Title</td>
<td>Investigator</td>
<td>Study Start Date</td>
<td>Status</td>
<td>Sponsor</td>
<td>Protocol Number</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>--------------------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>A Comparison of the Effect of Two Doses of Levalbuterol with Ventolin on Pulmonary Function in Subjects with Mild to Moderate Asthma</td>
<td>Lockey</td>
<td>6/30/1999</td>
<td>Closed - PI</td>
<td>Sepracor, Inc.</td>
<td>5084</td>
<td></td>
</tr>
<tr>
<td>A Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects with Co-Morbid Asthma and a History of Seasonal Exacerbations of Asthma on Medical Resources Utilization (for Asthma and SAR)</td>
<td>Lockey</td>
<td>5/4/1999</td>
<td>Closed - PI</td>
<td>Integrated Therapeutics Group, Incorporated</td>
<td>4962</td>
<td></td>
</tr>
<tr>
<td>[protocol no. L808, 065-011 #004] A Multicenter, Double-Blind, Placebo-Controlled Study Comparing the Clinical Effect of Nebulized L-808,065 in Patients with Chronic Asthma</td>
<td>Lockey</td>
<td>4/21/1999</td>
<td>Closed - PI</td>
<td>Merck &amp; Company, Inc.</td>
<td>5170</td>
<td></td>
</tr>
<tr>
<td>Understanding of Asthma Through Educational Intervention</td>
<td>Lockey</td>
<td>4/21/1999</td>
<td>Closed - PI</td>
<td>Integrated Therapeutics Group, Incorporated</td>
<td>4534</td>
<td></td>
</tr>
<tr>
<td>[protocol no. RG5016T 310, Azmacort HFA Study 204] A Phase II/III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Azmacort(R) (triamcinolone acetonide) HFA-134a Inhalation Aerosol 225 mcg, 460 mcg and 900 mcg Administered Once Daily for 12 Weeks in the Treatment of Mild Persistent and Moderate Persistent Asthma in 800 Adolescents and Adults</td>
<td>Lockey</td>
<td>3/3/1999</td>
<td>Closed - PI</td>
<td>Rhone-Poulenc Rorer Central Pharmaceuticals</td>
<td>4801</td>
<td></td>
</tr>
<tr>
<td>A Randomized, Open Label, Cross-Over Study Comparing the Parent/Guardian Preference for Montelukast Sodium Tablets or Cromolyn Sodium Aerosol (MDI) Treatment in their Children Ages 6 to 11 with Chronic Asthma</td>
<td>Lockey</td>
<td>3/3/1999</td>
<td>Closed - PI</td>
<td>Merck &amp; Company, Inc.</td>
<td>4437</td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>Investigator</td>
<td>Start Date</td>
<td>Status</td>
<td>Sponsor</td>
<td>Protocol No.</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>----------------------------------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Quantitative Intradermal Test Procedure to Evaluate Subject Sensitivity to Euroglyphus Maynei and Blomia Tropicalis House Dust Mites and to Determine the Biological Potency of Euroglyphus Maynei and Blomia Tropicalis Using the ID50EAL Method - A Single Center Trial</td>
<td>Lockey</td>
<td>2/28/1999</td>
<td>Closed - PI</td>
<td>Bayer Corporation</td>
<td>4032</td>
<td></td>
</tr>
<tr>
<td>Safety Evaluation of Once Daily Dosing of Fexofenadine HCl 180 mg in Subjects with Seasonal Allergic Rhinitis and Concomitant Mild to Moderate Asthma</td>
<td>Lockey</td>
<td>2/4/1999</td>
<td>Closed - PI</td>
<td>Hoechst-Marion Roussel, Inc.</td>
<td>5076</td>
<td></td>
</tr>
<tr>
<td>A Repeat-Dose, Dose-Ranging, Placebo-Controlled, Study of the Safety and Efficacy of SB 210396 in Patients with Chronic Severe Asthma</td>
<td>Lockey</td>
<td>10/21/1998</td>
<td>Closed - PI</td>
<td>Smithkline Beecham</td>
<td>4301</td>
<td></td>
</tr>
<tr>
<td>[protocol no. MK0476-031-20, extension] An Open, Controlled Extension to the MK-0476 versus Placebo Comparison Study to Investigate the Long-Term Safety and Tolerability of MK-0476 in Patients with Chronic Asthma</td>
<td>Lockey</td>
<td>10/21/1998</td>
<td>Closed - PI</td>
<td>Merck &amp; Company, Inc.</td>
<td>3633</td>
<td></td>
</tr>
<tr>
<td>Aerobid-Once-A-Day with AeroChamber in Mild to Moderate Asthma Patients</td>
<td>Lockey</td>
<td>9/15/1998</td>
<td>Closed - PI</td>
<td>Forest Laboratories, Inc.</td>
<td>4752</td>
<td></td>
</tr>
<tr>
<td>Treatment of Post-Viral Cough with Beclomethasone</td>
<td>Lockey</td>
<td>6/30/1998</td>
<td>Closed - PI</td>
<td>Glaxo Wellcome, Inc.</td>
<td>3437</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Investigator</td>
<td>Start Date</td>
<td>Status</td>
<td>Sponsor</td>
<td>NCT Number</td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>--------------------</td>
<td>-------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>MK-639-033</td>
<td>A Multi-Clinic Double-Blind Randomized Eighteen-Month Study in HIV-1 Seropositive Patients to Compare the Efficacy and Safety of MK-639 (800 mg q 8 h) and Zidovudine (200 mg q 8 h) Administered Concomitantly to MK-639 Alone and Zidovudine Alone</td>
<td>Lockey</td>
<td>5/4/1998</td>
<td>Closed - PI</td>
<td>Merck &amp; Company, Inc.</td>
<td>3791</td>
</tr>
<tr>
<td></td>
<td>A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Comparative Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Zafirlukast (20mg BID), in Subjects who are Currently Receiving Beta-Agonists Alone</td>
<td>Lockey</td>
<td>4/21/1998</td>
<td>Closed - PI</td>
<td>Glaxo Wellcome, Inc.</td>
<td>4670</td>
</tr>
<tr>
<td></td>
<td>12 Weeks Treatment with 250mg Roflumilast versus 500mg Roflumilast versus 10mg Montelukas versus Placebo in Patients with Asthma</td>
<td>Lockey</td>
<td>Closed - Never Opened</td>
<td>Byk Gulden Pharmaceuticals</td>
<td>6075</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12 Weeks Treatment with 250mg Roflumilast versus 500mg Roflumilast versus Placebo Added to 200mg Fluticasone Propionate in Patients with Asthma</td>
<td>Lockey</td>
<td>Closed - Never Opened</td>
<td>Byk Gulden Pharmaceuticals</td>
<td>6076</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Double-Blind, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of L-753099 in Patients With COPD</td>
<td>Lockey</td>
<td>Closed - Never Opened</td>
<td>Merck &amp; Company, Inc.</td>
<td>5669</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) in the Treatment of Viral Respiratory Infection in Children 1 to 6 Years of Age</td>
<td>Lockey</td>
<td>Disapproved</td>
<td>ViroPharma, Inc.</td>
<td>6324</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) in the Treatment of Viral Respiratory Infection in Children 7 to 12 Years of Age</td>
<td>Lockey</td>
<td>Disapproved</td>
<td>ViroPharma, Inc.</td>
<td>6325</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Randomized, Placebo-Controlled Study of the Safety and Immunologic Activity of a Single-Dose of Subcutaneous Recombinant Human Interleukin-12 (rhIL-12) Administered Concurrently with Cat Allergen in Patients Allergic to Cats</td>
<td>Lockey</td>
<td>1998</td>
<td>Closed - PI</td>
<td>Genetics Institute, Inc.</td>
<td>4708</td>
</tr>
<tr>
<td>Study Title</td>
<td>Sponsor</td>
<td>Protocol No.</td>
<td>Number</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>-----------------------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Randomized, Placebo-Controlled, Ascending-Dose Study of the Safety and Immunologic Activity of Nebulized Recombinant Human Interleukin-12 (rhIL-12) in Patients with Mild Asthma.</td>
<td>Genetics Institute, Inc.</td>
<td>5260</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. Aradigm 97-01] 1997 Effectiveness of the SmartMist Asthma Management System Combined With Inhaled Fluticasone Propionate vs. Aerochamber with Fluticasone Propionate in Moderate and Severe Asthmatics (Aradigm 97-01 Ver. 4/30/97)</td>
<td>Aradigm Corporation</td>
<td>4572</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy and Safety of Combination Loratadine/Montelukast QD vs. its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis</td>
<td>Schering-Plough Corporation</td>
<td>5927</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy and Safety of Combination Loratadine/Montelukast QD vs. its Components vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis</td>
<td>Schering-Plough Corporation</td>
<td>5920</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Efficacy of Disodium Octaborate Tetrahydrate (DOT) and Vacuum Cleaning in Lowering Dust House Mite Population and House Dust Mite Allergen Levels in Homes in Tampa, FL</td>
<td>Division Sponsored</td>
<td>100182</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti-Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents with Persistent Allergic Asthma</td>
<td>Schering-Plough Corporation</td>
<td>106475</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. CQAB149B2329] A 52-Week Treatment, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of Indacaterol (200 &amp; 400 ug o.d.) in Patients with Chronic Obstructive Pulmonary Disease Using Open Label Tiotropium (18 ug o.d.) As An Active Control - CQAB149B2329</td>
<td>Novartis Pharmaceutical Corporation</td>
<td>104337</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Description</td>
<td>Sponsor</td>
<td>Protocol Number</td>
<td>Status</td>
<td>Investigator</td>
<td>Institution</td>
<td>Code</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
<td>--------------</td>
<td>--------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>A Comparative Double-Blind, Double-Dummy Study of Desloratadine (DL) 4mg Once Daily, Cetirizine 10mg Once Daily and Placebo Once Daily in Patients with Chronic Idiopathic Urticaria (CIU)</td>
<td>Integrated Therapeutics Group, Incorporated</td>
<td>102386</td>
<td>Closed - Never Opened</td>
<td>Lockey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. XRP1526B/3030] A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160ug Administered for 12 Weeks Either In A Once-Daily Regimen in the Morning (160ug qd AM) Or In A Twice Daily Regimen (80 ug bid) in Adults and Adolescents with Mild to Moderate Persistent Asthma Treated Previously With Inhaled Corticosteroids - XRP1526B/3030</td>
<td>Aventis</td>
<td>103863</td>
<td>Closed - Never Opened</td>
<td>Lockey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A One Week, Double-Blind, Randomized, Placebo-Controlled Dose-Confirming Study to Determine the Efficacy and Safety of Oxis™ Turbuhaler® Administered to Children with Asthma</td>
<td>AstraZeneca Ltd.</td>
<td>6119</td>
<td>Closed - Never Opened</td>
<td>Lockey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A One Week, Double-Blind, Randomized, Placebo-Controlled, Dose-Confirming Study to Determine the Efficacy and Safety of Oxis™ Turbuhaler® Administered to Adults and Adolescents with Asthma</td>
<td>AstraZeneca Ltd.</td>
<td>6112</td>
<td>Closed - Never Opened</td>
<td>Lockey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. FFA109684] A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy</td>
<td>GlaxoSmithKline</td>
<td>106484</td>
<td>Closed - Never Opened</td>
<td>Lockey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Year</td>
<td>Study Design</td>
<td>Investigator</td>
<td>Sponsor</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>------</td>
<td>--------------</td>
<td>--------------</td>
<td>---------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>FFA20003</td>
<td>2006</td>
<td>Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg, 400mcg, 600mcg and 800mcg Administered Once Daily in the Morning and Fluticasone Propionate 500mcg BID via DISCUS Inhalation Powder Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (&gt;=12 years old) with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy</td>
<td>Lockey</td>
<td>Closed - Never Opened</td>
<td>GlaxoSmithKline</td>
<td></td>
</tr>
<tr>
<td>FFA100240</td>
<td>2006</td>
<td>Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 25mcg, 50mcg, 100mcg and 200mcg Administered Once Daily in the Morning and Fluticasone Propionate 100mcg BID via DISKUS Inhalation Powder Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (=12 years old) with Persistent Asthma Symptomatic on NON-ICS Therapy</td>
<td>Lockey</td>
<td>Closed - Never Opened</td>
<td>GlaxoSmithKline</td>
<td></td>
</tr>
<tr>
<td>BY217/M2-023</td>
<td>2005</td>
<td>Randomized, Controlled Study of Roflumilast (250 mcg and 500 mcg) versus Placebo in Patients with Asthma</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>Altana Pharma</td>
<td></td>
</tr>
<tr>
<td>D5896C00001 D5 GEMINI</td>
<td>2006</td>
<td>Randomized, Double-Blind, Active-Controlled, Parallel-Group, Single-Dummy, Multicenter, 12 Week Study to Assess the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 ug x 2 Actuations Once-Daily (QD) Compared to SYMBICORT pMDI 80/4.5 ug x 2 Actuations QD, SYMBICORT pMDI 80/4.5 ug x 2 Actuations Twice-Daily (BID) and to Budesonide pMDI 160 ug x 2 Actuations QD in Asthmatic Subjects 12 Years of Age and Older</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>AstraZeneca Ltd.</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Title</td>
<td>Investigator</td>
<td>Status</td>
<td>Sponsor</td>
<td>ID</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------</td>
<td>--------</td>
<td>--------------------------------</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td>FFU105927</td>
<td>[protocol no. FFU105927] Never started A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, One-Week, Cross-Oer, Multi-Center Study to Evaluate the Efficacy and Experience of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200 mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis (FF105927)</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>GlaxoSmithKline</td>
<td>105988</td>
<td></td>
</tr>
<tr>
<td>CQAB149B2205</td>
<td>[protocol no. CQAB149B2205] A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Multiple Dose (7 days) Dose-Ranging Study, To Assess the Efficacy and Safety of 4 Doses of QAB149 (50, 100, 200 &amp; 400 ug) Delivered via a Multiple Dose Inhaler and 1 Dose of QAB149 (400 ug) Delivered via a Single Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD) - CQAB149B2205</td>
<td>Lockey</td>
<td>Closed - PI</td>
<td>Novartis Pharmaceutical Corporation</td>
<td>102698</td>
<td></td>
</tr>
<tr>
<td>SKY 2028-004</td>
<td>[protocol no. SKY 2028-004] 2008 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Stratified, Multi-Center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 100/10ug or 250/10ug twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Placebo or Fluticasone (250ug twice daily) and Formoterol (10ug twice daily) Alone in Adolescent and Adult Patients with Moderate to Severe Asthma - sky2028-004</td>
<td>Lockey</td>
<td>Closed - Never Opened</td>
<td>Skye Pharma, Inc.</td>
<td>104408</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis</td>
<td>Lockey</td>
<td>Closed - Never Opened</td>
<td>GlaxoSmithKline</td>
<td>106532</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Lead Investigator</td>
<td>Study Completion Year</td>
<td>Sponsor</td>
<td>Clinicaltrials.gov Identifier</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------</td>
<td>----------------------</td>
<td>--------------------------------------</td>
<td>-------------------------------</td>
<td></td>
</tr>
<tr>
<td>FFR100010</td>
<td>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects ages 2 to &lt;12 Years with Seasonal Allergic Rhinitis (SAR)</td>
<td>Lockey</td>
<td>2005</td>
<td>GlaxoSmithKline</td>
<td>103386</td>
<td></td>
</tr>
<tr>
<td>FFR30002</td>
<td>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mg for 4 weeks in Adult and Adolescent Subjects (≥12 years of age) with Perennial Rhinitis</td>
<td>Lockey</td>
<td>2005</td>
<td>GlaxoSmithKline</td>
<td>103264</td>
<td></td>
</tr>
<tr>
<td>SD-0040764</td>
<td>A Randomized, Partly Blinded, Multicenter, Parallel Study Comparing the Efficacy and Safety of PULMICORT RESPULES® (budesonide inhalation suspension) at 0.5 mg, QD, 1.0 mg QD, 1.0 mg BID, 2.0 mg BID and PULMICORT TURBUHALER® (budesonide) at 400 mcg BID in Adolescents (12 Years of Age and Older) and Adults with Moderate to Severe Asthma</td>
<td>Lockey</td>
<td>2004</td>
<td>AstraZeneca Ltd.</td>
<td>102357</td>
<td></td>
</tr>
<tr>
<td>SFA100316</td>
<td>A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects with Activity Induced Bronchospasm</td>
<td>Lockey</td>
<td>2005</td>
<td>GlaxoSmithKline</td>
<td>101998</td>
<td></td>
</tr>
<tr>
<td>MRE0470P-203</td>
<td>A Two-Part Study to Evaluate the Safety of Binodenoson (MRE0470) in Adult Subjects With Mild, Intermittent Asthma</td>
<td>Lockey</td>
<td>2003</td>
<td>King Pharmaceuticals Research and Development, Inc.</td>
<td>101766</td>
<td></td>
</tr>
<tr>
<td>Study Title</td>
<td>Sponsor</td>
<td>Status</td>
<td>End Date</td>
<td>Protocol No.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>----------</td>
<td>--------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase I, Open-Label Investigation of Safety and Pharmacokinetics of Lyophilized Korean Green Cross Intravenous Immune Globulin 5% Solution in Patients with Primary Immunodeficiency Disorders</td>
<td></td>
<td>Closed - Never Opened</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procalcitonin Level as a Diagnostic Aid in Acute Bacterial Sinusitis</td>
<td></td>
<td>Closed - Never Opened</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. A2-8397-CAT] Prospective Validation Study of the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) in Stable and Exacerbating Patients</td>
<td></td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhinitis and Sinusitis in Asthma</td>
<td></td>
<td>Closed - Never Opened</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. SARA] Study of Acid Reflux and Asthma (SARA)</td>
<td></td>
<td>American Lung Association</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic Reactions in Allergen Immunotherapy</td>
<td></td>
<td>Division Sponsored</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Leukotriene Modifier Or Corticosteroids or Corticosteroid-Salmeterol Trial (The LOCCS Trial)</td>
<td></td>
<td>American Lung Association</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol ID</td>
<td>Investigator</td>
<td>Date</td>
<td>Status</td>
<td>Sponsor</td>
<td>designer no.</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>--------------</td>
<td>------</td>
<td>--------</td>
<td>---------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>Formoterol 37-3027, proj. no. 843-32</td>
<td>Lockey</td>
<td>1994</td>
<td>Closed</td>
<td>Astra, USA</td>
<td>3428</td>
<td></td>
</tr>
<tr>
<td>Formoterol Turbuhaler 6, 12, and 24 mcg administered twice daily in patients with asthma</td>
<td>Lockey</td>
<td>04/09/2012</td>
<td>Approved, Open</td>
<td>GlaxoSmithKline</td>
<td>20120370</td>
<td></td>
</tr>
<tr>
<td>HZA106853: A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy</td>
<td>Lockey</td>
<td>03/12/2012</td>
<td>Approved, Open</td>
<td>GlaxoSmithKline</td>
<td>20120172</td>
<td></td>
</tr>
<tr>
<td>GB27862: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA WHO ARE ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION</td>
<td>Lockey</td>
<td>01/25/2012</td>
<td>Approved, Open</td>
<td>GlaxoSmithKline Research &amp; Development Limited</td>
<td>20112136</td>
<td></td>
</tr>
<tr>
<td>SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma</td>
<td>Lockey</td>
<td>11/18/2011</td>
<td>Approved, Open</td>
<td>GlaxoSmithKline Research &amp; Development Limited</td>
<td>20111924</td>
<td></td>
</tr>
<tr>
<td>SAS115358: A 6-month safety and benefit study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma</td>
<td>Lockey</td>
<td>2007</td>
<td>Closed</td>
<td>GlaxoSmithKline</td>
<td>20072255</td>
<td></td>
</tr>
<tr>
<td>FFR101782: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis</td>
<td>Lockey</td>
<td>10/13/2011</td>
<td>Approved, Open</td>
<td>GlaxoSmithKline</td>
<td>20111381</td>
<td></td>
</tr>
<tr>
<td>HGT-FIR-086: A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with</td>
<td>Lockey</td>
<td></td>
<td></td>
<td>Shire Orphan Therapies, Inc</td>
<td>20111381</td>
<td></td>
</tr>
<tr>
<td>Study ID</td>
<td>Study Description</td>
<td>Sponsor</td>
<td>Status</td>
<td>Approval Date</td>
<td>Approval Number</td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>--------------</td>
<td>---------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>A6631029</td>
<td>A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 FOR 12 WEEKS IN ADULTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ON A BACKGROUND OF SALMETEROL ZINOFOATE/FLUTICASONE PROPIONATE COMBINATION</td>
<td>Pfizer Limited</td>
<td>Approved, Open</td>
<td>2011</td>
<td>20111229</td>
<td></td>
</tr>
<tr>
<td>HZC113782</td>
<td>A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease</td>
<td>GlaxoSmithKline</td>
<td>Approved, Open</td>
<td>2011</td>
<td>20110383</td>
<td></td>
</tr>
<tr>
<td>FFA109684</td>
<td>A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy</td>
<td>GlaxoSmithKline</td>
<td>Closed</td>
<td>2008</td>
<td>20080317</td>
<td></td>
</tr>
<tr>
<td>Study ID</td>
<td>Description</td>
<td>Sponsor</td>
<td>Status</td>
<td>Date</td>
<td>Approval Status</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
<td>----------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>ACT11457</td>
<td>A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of SAR231893/REGN668 administered subcutaneously (SC) once weekly for 12 weeks in patients with persistent moderate to severe eosinophilic asthma who are partially controlled/uncontrolled by inhaled corticosteroid (ICS) plus long-acting beta2 agonist (LABA) therapy</td>
<td>Sanofi-aventis, US, Inc.</td>
<td>Approved</td>
<td>08/16/2011</td>
<td>Open</td>
<td>Sanofi-aventis, US, Inc.</td>
</tr>
<tr>
<td>C1 1310</td>
<td>A Phase IIIb randomized, double-blind, placebo-controlled study with an open-label extension evaluating the efficacy, safety and immunogenicity of recombinant human C1 inhibitor for the treatment of acute attacks of angioedema in patients with HAE</td>
<td>Pharming Technologies B.V.</td>
<td>Approved</td>
<td>01/04/2011</td>
<td>Open</td>
<td>Pharming Technologies B.V.</td>
</tr>
<tr>
<td>P06476</td>
<td>A Randomized, Evaluator-Blind, Crossover, Single Dose Study of the Bronchodilator Effect of Formoterol Fumarate in Combination With Mometasone Furoate Metered Dose Inhaler Delivered With and Without a Spacer Versus Placebo and Foradil® Aerolizer® in Children With Persistent Asthma</td>
<td>Schering Plough Research Institute, a Division of Schering Corporation</td>
<td>Closed</td>
<td>2010</td>
<td></td>
<td>Schering Plough Research Institute, a Division of Schering Corporation</td>
</tr>
<tr>
<td>[protocol no. MI-CP186]</td>
<td>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563, A Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, on Asthma Control Following Acute Exacerbations in Adults</td>
<td>MedImmune</td>
<td>Closed</td>
<td>2009</td>
<td></td>
<td>MedImmune</td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Title</td>
<td>Sponsor</td>
<td>Status</td>
<td>Approval Date</td>
<td>Investigator</td>
<td>20100683</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>------------</td>
<td>---------------</td>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>205.452</td>
<td>A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 μg and 5 μg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 μg delivered by the HandiHaler®</td>
<td>Boehringer Ingelheim Pharmaceuticals, Inc.</td>
<td>Closed</td>
<td>2010</td>
<td>Lockey</td>
<td></td>
</tr>
<tr>
<td>1184.15</td>
<td>1184.15: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double-blind, parallel group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5μg/25 μg) Inhalation Powder in the morning (PE capsule via tiotropium/salmeterol HandiHaler®), Tiotropium (18 μg) Inhalation Powder in the morning (gelatin capsule via Spiriva® HandiHaler®), Salmeterol Inhalation (25 μg) Powder in the morning and evening (PE capsule via tiotropium/salmeterol HandiHaler®) and Tiotropium/Salmeterol (7.5 μg/25 μg) Inhalation Powder in the morning (PE capsule via tiotropium/salmeterol HandiHaler®) plus Salmeterol (25 μg) Inhalation Powder in the evening (PE capsule via tiotropium/salmeterol HandiHaler®) in patients with COPD</td>
<td>Boehringer Ingelheim Pharmaceuticals, Inc.</td>
<td>Closed</td>
<td>2008</td>
<td>Lockey</td>
<td></td>
</tr>
<tr>
<td>A7881013</td>
<td>A7881013: A PHASE 2B, PARALLEL, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE COMPARATOR AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND EFFICACY OF 6-WEEK QD ADMINISTRATION OF PF-00610355 CRC-749 DPI IN PATIENTS WITH MODERATE COPD</td>
<td>Pfizer</td>
<td>Closed</td>
<td>2010</td>
<td>Lockey</td>
<td></td>
</tr>
<tr>
<td>DX-88/24</td>
<td>DX-88/24: A Phase 4, Long-Term Observational Safety Study to Evaluate Immunogenicity and Hypersensitivity with Exposure to KALBITOR (ecallantide) for</td>
<td>Dyax Corp.</td>
<td>Approved, Open</td>
<td>05/10/2010</td>
<td>Lockey</td>
<td>20092375</td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Description</td>
<td>Lead Investigator</td>
<td>Status</td>
<td>Sponsor</td>
<td>Code</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
<td>------------------</td>
<td>--------</td>
<td>---------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>DX-88/19</td>
<td>Patient Long Term Continuation of DX-88 (Ecallantide) for acute hereditary or acquired angioedema attacks</td>
<td>Lockey</td>
<td>Closed</td>
<td>Dyax Corp.</td>
<td>20062187</td>
<td></td>
</tr>
<tr>
<td>DX-88/14</td>
<td>Evaluation of DX-88’s effects in mitigating angioedema. A double-blind, placebo-controlled study followed by a repeat dosing phase to assess efficacy and safety of DX-88 (recombinant plasma kallikrein inhibitor) for the treatment of acute attacks of hereditary angioedema</td>
<td>Lockey</td>
<td>Closed</td>
<td>Dyax Corp.</td>
<td>20052247</td>
<td></td>
</tr>
<tr>
<td>MI CP-143</td>
<td>A phase 2A, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety and effect on exercise challenge testing of multiple fixed subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in adults with stable asthma and exercise-induced bronchoconstriction</td>
<td>Lockey</td>
<td>Closed</td>
<td>MedImmune</td>
<td>20080592</td>
<td></td>
</tr>
<tr>
<td>091-061</td>
<td>A multicenter, double-blind, double-dummy, randomized, active-controlled, parallel group long-term safety study of 15 µg and 25 µg arformoterol tartrate inhalation solution BID in the treatment of subjects with chronic obstructive pulmonary disease</td>
<td>Lockey</td>
<td>Closed</td>
<td>Sepracor</td>
<td>20052090</td>
<td></td>
</tr>
<tr>
<td>ADA103578</td>
<td>A multicenter, randomized, double-blind, triple-dummy, placebo-controlled, parallel group, four-week study assessing the efficacy of fluticasone propionate aqueous nasal spray 200 mcg QD versus montelukast 10 mg QD in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving ADVAIR Diskus 100/50 mcg BID or placebo BID</td>
<td>Lockey</td>
<td>Closed</td>
<td>GlaxoSmithKline</td>
<td>20051857</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Title</td>
<td>Sponsor</td>
<td>Year</td>
<td>Status</td>
<td>Company</td>
<td>Code</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------------------------------------------------</td>
<td>------------------------</td>
<td>------</td>
<td>----------</td>
<td>--------------------</td>
<td>--------</td>
</tr>
<tr>
<td>DX-88/20</td>
<td>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of DX-88 (Ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema.</td>
<td>Dyax Corp.</td>
<td>2008</td>
<td>Closed</td>
<td></td>
<td>20062444</td>
</tr>
<tr>
<td>FFA109687</td>
<td>A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 100mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal Asthma Therapy</td>
<td>GlaxoSmithKline</td>
<td>2008</td>
<td>Closed</td>
<td></td>
<td>20080274</td>
</tr>
<tr>
<td>B2C111045</td>
<td>A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD</td>
<td>GlaxoSmithKline</td>
<td>2008</td>
<td>Closed</td>
<td></td>
<td>20080240</td>
</tr>
<tr>
<td>MEE103219</td>
<td>A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years</td>
<td>GlaxoSmithKline</td>
<td>2008</td>
<td>Closed</td>
<td></td>
<td>20061258</td>
</tr>
<tr>
<td>VAL-P-03-103</td>
<td>Interview study to explore the content validity of visual analogue scales to assess severity of hereditary angioedema (HAE) in adults in the USA and Italy</td>
<td>Pharming Technologies B.V.</td>
<td>2009</td>
<td>Closed</td>
<td></td>
<td>20091584</td>
</tr>
<tr>
<td>CQAB149B2351</td>
<td>A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150μg once daily with open label tiotropium 18μg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease</td>
<td>Novartis Pharmaceutical corporation</td>
<td>2009</td>
<td>Closed</td>
<td></td>
<td>20090658</td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Investigator</td>
<td>Year</td>
<td>Status</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>------</td>
<td>--------</td>
<td>----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>SB 205312/070</td>
<td>A multi-center, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of two doses of SB205312 administered as an oral suspension (75 mg BID and 150 mg BID) for 12 weeks in pediatric outpatients with asthma</td>
<td>Lockey</td>
<td>1997</td>
<td>Closed</td>
<td>SmithKline Beecham</td>
<td></td>
</tr>
<tr>
<td>LO269</td>
<td>A double-blind, parallel, multicenter study of the safety and efficacy of cetirizine and clemastine versus placebo in the treatment of seasonal allergic rhinitis in children</td>
<td>Lockey</td>
<td>1993</td>
<td>Closed</td>
<td>Pfizer</td>
<td></td>
</tr>
<tr>
<td>P94-142-17</td>
<td>A phase IV, double-blind, placebo-controlled, double-dummy, comparison of clinical efficacy and safety of Vanceril MDI versus Azmacort MDI in adult asthmatics</td>
<td>Lockey</td>
<td>1995</td>
<td>Closed</td>
<td>Schering</td>
<td></td>
</tr>
<tr>
<td>PDA-641/0805-A-205-US</td>
<td>A comparison of the safety and efficacy of two oral doses of PDA-641 10 mg and 30 mg TID and placebo in mild to moderate asthmatics</td>
<td>Lockey</td>
<td>1996</td>
<td>Closed</td>
<td>Wyeth-Ayerst</td>
<td></td>
</tr>
<tr>
<td>MK 031-01</td>
<td>A multicenter, double-blind, randomized, parallel group study comparing the clinical effect of MK-0476 and placebo in patient with chronic asthma</td>
<td>Lockey</td>
<td>1994</td>
<td>Closed</td>
<td>Merck Research Laboratories</td>
<td></td>
</tr>
<tr>
<td>Rhinocort 05-3046-3047</td>
<td>A randomized, open-label, comparison of rhinocort budesonide aqua pump spray versus NASALCROM (cromolyn sodium) in treatment of children with perennial rhinitis</td>
<td>Lockey</td>
<td>1995</td>
<td>Closed</td>
<td>Astra USA</td>
<td></td>
</tr>
<tr>
<td>M94199</td>
<td>A long-term, surveillance study of Zileuton + usual care versus usual care in patients with asthma</td>
<td>Lockey</td>
<td>1995</td>
<td>Closed</td>
<td>Abbott Laboratories</td>
<td></td>
</tr>
<tr>
<td>PJPR0053</td>
<td>A double-blind, randomized study comparing the efficacy and safety of Fexofenadine and placebo in black patients with seasonal allergic rhinitis</td>
<td>Lockey</td>
<td>1996</td>
<td>Closed</td>
<td>Hoechst-Marion Roussel, Inc.</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Description</td>
<td>Sponsor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEPROO51</td>
<td>A multicenter, double-blind, placebo-controlled study of Accolate in mild to moderate asthmatic patients needing chronic treatment 13-week efficacy and up to 1 year open-label safety study extension</td>
<td>Marion Merrill Dow, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLD402</td>
<td>A placebo-controlled, double-blind, randomized, parallel study comparing duration and action and safety and efficacy of four dose strengths of Terfenadine in the treatment of fall allergies</td>
<td>Glaxo, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLGA5013</td>
<td>A randomized, double-blind, placebo-controlled, parallel-group evaluation of the effects of salmeterol on methacholine induced bronchial hyperresponsiveness over 24-weeks in adolescents and adults subjects with asthma</td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miles</td>
<td>A double-blind, randomized, placebo-controlled trial in the safety and efficacy of oral bay x 1005 100mg BID versus 250mg BID versus 500mg BID versus placebo BID for six-weeks in patients with asthma</td>
<td>Bayer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accolate 579394</td>
<td>A multicenter, double-blind efficacy trial to compare accolate given at 160mg per day with placebo over 13-weeks in subjects with chronic severe asthma</td>
<td>Zeneca Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>847</td>
<td>A randomized, double-blind, parallel-comparison of atrovent nasal spray 0.06% and 0.12% 84mcg versus 168 mcg per nostril respectively versus placebo BID in allergic perennial allergic rhinitis</td>
<td>Boehringer Ingelheim</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol no.</td>
<td>Description</td>
<td>Sponsor</td>
<td>Year</td>
<td>Status</td>
<td>Additional Information</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>------</td>
<td>-----------</td>
<td>---------------------------------------</td>
<td></td>
</tr>
<tr>
<td>GS9310</td>
<td>A clinical use study comparing nasalcrom nasal solution 4% to placebo nasal solution in treatment of the symptoms associated with seasonal allergic rhinitis.</td>
<td>Lockey</td>
<td>1995</td>
<td>Closed</td>
<td>Wallace</td>
<td></td>
</tr>
<tr>
<td>SLGA 4005</td>
<td>A randomized, double-blind, double-dummy, comparative clinical trial of a 12-week course of salmeterol xinafoate versus ipratropium Bromide versus placebo PRN Ventolin in subjects with chronic obstructive pulmonary disease.</td>
<td>Lockey</td>
<td>1995</td>
<td>Closed</td>
<td>Glaxo Wellcome</td>
<td></td>
</tr>
<tr>
<td>DF12588, proj. no. 2446</td>
<td>A multi-center, double-blind, placebo-controlled, dose ranging study to assess and compare the activity of an oral administration FR27417-2.5, 10 and 30mg once a day during 12 weeks in moderate asthmatic patients.</td>
<td>Lockey</td>
<td>1995</td>
<td>Closed</td>
<td>Sanofi/Innovex, Inc.</td>
<td></td>
</tr>
<tr>
<td>V211-017-0030</td>
<td>V211-017-0030: A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live in Patients on Chronic/Maintenance Corticosteroids.</td>
<td>Lockey</td>
<td>2010</td>
<td>Closed</td>
<td>Merck &amp; Co.</td>
<td></td>
</tr>
<tr>
<td>048-076</td>
<td>Terfenadine Urticaria Study</td>
<td>Lockey</td>
<td>1986</td>
<td>Closed, destroyed</td>
<td>Merrill-Dow</td>
<td></td>
</tr>
<tr>
<td>85-N-0039</td>
<td>Cetirizine Urticaria Study</td>
<td>Lockey</td>
<td>1980</td>
<td>Closed, destroyed</td>
<td>Pfizer</td>
<td></td>
</tr>
<tr>
<td>ANC-MD-07-000</td>
<td>A One-Year, Open-Label Study to Evaluate the Safety of HFA Flunisolide in Children with Mild to Moderate Asthma</td>
<td>Lockey</td>
<td>1999</td>
<td>Closed</td>
<td>Forest Research Institute</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Author</td>
<td>Year</td>
<td>Status</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------</td>
<td>------</td>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>MO16455/4092</td>
<td>The effects of once daily dosing of fexofenadine HCl in patients with seasonal allergic rhinitis and concomitant mild to moderate asthma</td>
<td>Lockey</td>
<td>2002</td>
<td>Closed</td>
<td>Hoechst Marion Roussel</td>
<td></td>
</tr>
<tr>
<td>M90-460</td>
<td>5-Lipoxygenase Inhibitor Zileuton (Abbott-64077): A Phase II Study on the Safety and Efficacy of Zileuton (ABBOTT-64077), 800mg B.I.D. or 600mg Q.I.D. versus Placebo in the Treatment of Moderate Asthma</td>
<td>Lockey</td>
<td>1990</td>
<td>Closed</td>
<td>Abbott Laboratories</td>
<td></td>
</tr>
<tr>
<td>C88-069-04</td>
<td>The Efficacy of SCH 37224 in Mild to Moderate Asthma</td>
<td>Lockey</td>
<td>1988</td>
<td>Closed</td>
<td>Schering Corp.</td>
<td></td>
</tr>
<tr>
<td>888-201-3</td>
<td>A Multicenter, Double-Blind, Three Month Study of the Comparative Efficacy and Safety of Procaterol and Albuterol Aerosol Administered QID in Outpatients with Reversible Bronchial Airway Obstruction</td>
<td>Lockey</td>
<td>1989</td>
<td>Closed</td>
<td>Parke-Davis Pharmaceutical</td>
<td></td>
</tr>
<tr>
<td>AU-115, Ridaura</td>
<td>Auranofin versus Placebo in the Treatment of Steroid-Dependent Asthma</td>
<td>Lockey</td>
<td>1989</td>
<td>Closed</td>
<td>Smith Kline &amp; French Laboratories</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Description</td>
<td>Investigator</td>
<td>Year</td>
<td>Status</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>------</td>
<td>----------</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>9188IL/0028</td>
<td>A Multicenter, Randomized, Double-Blind Study to Compare the Effect of Oral Doses of ICI 204,219 with Placebo Over 13 weeks in Subjects with Mild to Moderate Asthma</td>
<td>Lockey</td>
<td>1992</td>
<td>Closed</td>
<td>Zeneca Pharmaceuticals Group</td>
<td></td>
</tr>
<tr>
<td>SLGA 4004/4005</td>
<td>A randomized, double-blind, double-dummy, comparative clinical trial of a 12-week course of salmeterol xinafoate versus ipratropium Bromide versus placebo PRN ventolin in subjects with chronic obstructive pulmonary disease</td>
<td>Lockey</td>
<td>1995</td>
<td>Closed</td>
<td>GlaxoSmithKline</td>
<td></td>
</tr>
<tr>
<td>01029</td>
<td>Randomized, Multiple-Dose, Double-Blind Comparison of COMBIVENT® and Ventolin® in a Four Week, Parallel Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)</td>
<td>Lockey</td>
<td>1993</td>
<td>Closed</td>
<td>Boehringer Ingelheim</td>
<td></td>
</tr>
<tr>
<td>120-01/SNG 477</td>
<td>A Randomized, Double-Blind, Multicenter Study to Evaluate the Effect of Adding Either Montelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics</td>
<td>Lockey</td>
<td>2000</td>
<td>Closed</td>
<td>Merck &amp; Co.</td>
<td></td>
</tr>
<tr>
<td>M/5900/0003</td>
<td>The treatment of AIDS associated cachexia patients with halotestin tablets</td>
<td>Lockey</td>
<td>1992</td>
<td>Closed</td>
<td>Upjohn Company</td>
<td></td>
</tr>
<tr>
<td>BW825</td>
<td>Burroughs Wellcome Study</td>
<td>Lockey</td>
<td>1984</td>
<td>Closed</td>
<td>Burroughs Wellcome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Double-blind parallel study (Rotcap Study) and subcutaneous injectable study</td>
<td>Lockey</td>
<td>1984</td>
<td>Closed</td>
<td>Glaxo</td>
<td></td>
</tr>
<tr>
<td>AI414-144</td>
<td>Multicenter, Three-Arm, Comparative Study of Cefprozil 250mg BID or 500mg BID versus Amoxicillin/Clavulanate</td>
<td>Lockey</td>
<td>1993</td>
<td>Closed</td>
<td>Bristol Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>Study Title</td>
<td>Author</td>
<td>Year</td>
<td>Status</td>
<td>Sponsor</td>
<td>Protocol No</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>--------</td>
<td>------</td>
<td>---------</td>
<td>------------------</td>
<td>---------------------------</td>
<td></td>
</tr>
<tr>
<td>Potassium 500mg TID in the treatment of Acute and Uncomplicated Maxillary Sinusitis</td>
<td>Lockey</td>
<td>1993</td>
<td>Closed</td>
<td>Univax Biologics</td>
<td>UNX-2405</td>
<td></td>
</tr>
<tr>
<td>A Comparison of the Safety and Efficacy of the 2 Immune Globulin Intravenous Human Preparations (Unigam and Gammar ID) in Primary Immunodeficiency Patients</td>
<td>Lockey</td>
<td>1993</td>
<td>Closed</td>
<td>Sterling Winthrop</td>
<td>SEPR0051</td>
<td></td>
</tr>
<tr>
<td>Bronkometer Isoepharine Six-Week Trial of Pediatric Asthmatic Patients PD-663</td>
<td>Lockey</td>
<td>1986</td>
<td>Closed</td>
<td>Glaxo SmithKline</td>
<td>FLI-301</td>
<td></td>
</tr>
<tr>
<td>A placebo-controlled, double-blind, randomized, parallel study comparing the duration of action in safety and efficacy of four dose strengths of Terfenadine in the treatment of fall allergies</td>
<td>Lockey</td>
<td>1990</td>
<td>Closed</td>
<td>Pfizer</td>
<td>RG5016-112</td>
<td></td>
</tr>
<tr>
<td>A randomized, double-blind, comparative trial of two doses of inhaled Fluticasone Propionate and Placebo in Adolescent and Adult Patients with Mild to Moderate Asthma</td>
<td>Lockey</td>
<td>1991</td>
<td>Closed</td>
<td>Pfizer</td>
<td>RG5016-112</td>
<td></td>
</tr>
<tr>
<td>A double-blind, double-dummy, parallel group evaluation of the clinical equivalent of albuterol aerosol delivery through the standard BK300 valve or through the redesigned BK356 valve</td>
<td>Lockey</td>
<td>1992</td>
<td>Closed</td>
<td>Pfizer</td>
<td>RG5016-112</td>
<td></td>
</tr>
<tr>
<td>A double-blind, parallel, multicenter study of the safety and efficacy of Cetirizine 5mg versus Cetirizine 10mg versus Astemizole 10mg in the treatment of Seasonal Allergic Rhinitis</td>
<td>Lockey</td>
<td>1989</td>
<td>Closed</td>
<td>Pfizer</td>
<td>RG5016-112</td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Year</td>
<td>Status</td>
<td>Sponsor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------</td>
<td>--------</td>
<td>--------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C91-218-05</td>
<td>Proventil Repetabs for the prevention of the nocturnal symptoms of asthma</td>
<td>1992</td>
<td>Closed</td>
<td>Schering Plough</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLTA 4031</td>
<td>A randomized, double-blind, double-dummy, placebo-controlled, parallel group, comparative study of inhaled fluticasone propionate 88mcg BID versus Zafirlukast 20 mg BID in subjects who currently receiving beta agonists alone</td>
<td>1997</td>
<td>Closed</td>
<td>Glaxo Wellcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMART, SMG 477</td>
<td>A randomized, double-blind, multicenter to evaluate the effect of adding either montelukast sodium or salmeterol xinafoate to inhaled fluticasone on adult asthmatics</td>
<td>2000</td>
<td>Closed</td>
<td>Merck</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLGA 5007</td>
<td>A double-blind, parallel group evaluation of salmeterol versus placebo in the treatment of nocturnal asthma</td>
<td>1994</td>
<td>Closed</td>
<td>Glaxo SmithKline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABS-AS-304</td>
<td>A 12-week comparison of the efficacy and safety and steady-state Pharmacokinetics of albuterol Spiromax® and placebo in subjects 12 years and older with persistent asthma with steady state pharmacokinetics assessments</td>
<td>2012</td>
<td>Closed</td>
<td>Teva Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>VR506/2/004</th>
<th>A randomized double-blind, parallel group, dose-ranging study to evaluate the efficacy and safety of three different total daily doses of fluticasone propionate inhaled from a new dry powder inhaler in subjects with severe persistent asthma requiring oral corticosteroid therapy</th>
<th>2012</th>
<th>Open</th>
<th>Vectura Limited (Vectura”)</th>
<th>2012078</th>
</tr>
</thead>
<tbody>
<tr>
<td>[protocol no. KB003-04]</td>
<td>A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety Tolerability, and Efficacy of KB003 in Subjects with Asthma Inadequately Controlled by Corticosteroids.</td>
<td>Lockey 2012 Closed KaloBios Pharmaceuticals, Inc.</td>
<td>20120727</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. A6631033]</td>
<td>A Phase 2B, Randomized, Double-Blind, Double-Dynnt, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Daily Orally Administered PH-797804 for 12 Weeks in Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) on a Background of Tiotropium Bromide.</td>
<td>Lockey 2012 Closed Pfizer, Inc/</td>
<td>20120635</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[protocol no. HZA 106853]</td>
<td>A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy.</td>
<td>Lockey 2012 Open GlaxoSmithKline</td>
<td>20120370</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol No.</td>
<td>Study Title</td>
<td>Sponsor</td>
<td>Status</td>
<td>Sponsor Details</td>
<td>Protocol No.</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------------------------------------</td>
<td>-------------</td>
<td>-----------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>SAS115358</td>
<td>A 6-Month Safety and Benefit Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 years Old with Persistent Asthma.</td>
<td>GlaxoSmithKline Research &amp; Development Limited</td>
<td>Open</td>
<td>20111924</td>
<td></td>
</tr>
<tr>
<td>HGT-FIR-086</td>
<td>A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with Hereditary Angioedema</td>
<td>Shire Orphan Therapies, Inc.</td>
<td>Open</td>
<td>20111381</td>
<td></td>
</tr>
<tr>
<td>A6631029</td>
<td>A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Daily Orally Administered PH-797804 for 12 Weeks in Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) on a Background of Salmeterol Xinofoate/Fluticasone Propionate Combination.</td>
<td>Pfizer Limited</td>
<td>Closed</td>
<td>20111229</td>
<td></td>
</tr>
<tr>
<td>HZC113782</td>
<td>A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25 mcg with Placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary disease (COPD) and a History of at Increased Risk for Cardiovascular Disease.</td>
<td>GlaxoSmithKline</td>
<td>Open</td>
<td>20110383</td>
<td></td>
</tr>
<tr>
<td>C1 1310</td>
<td>A Phase IIIb Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients with HAE.</td>
<td>Pharming Technologies B.V.</td>
<td>Closed</td>
<td>20102041</td>
<td></td>
</tr>
<tr>
<td>MI-CP220/D3250L00001</td>
<td>A Phase 2b, Dose-Ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults with Uncontrolled Asthma.</td>
<td>Medimmune, LLC, an affiliate of AstraZeneca AB</td>
<td>Closed</td>
<td>20101198</td>
<td></td>
</tr>
<tr>
<td>Protocol no.</td>
<td>Study Title</td>
<td>Investigator</td>
<td>Year</td>
<td>Status</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------</td>
<td>------</td>
<td>---------</td>
<td>----------------</td>
</tr>
<tr>
<td>DX-88/24</td>
<td>A Phase 4, Long-Term Observational Safety Study to Evaluate Immunogenicity and Hypersensitivity with Exposure to KALBITOR (ecallantide) for the Treatment of Acute Attacks of HAE.</td>
<td>Lockey</td>
<td>2009</td>
<td>Closed</td>
<td>Dyax Corp.</td>
</tr>
</tbody>
</table>